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ABSTRACT 
 
Arrestins are multifunctional signaling proteins, important for the regulation of 
signal transduction and the trafficking of G protein-coupled receptors (GPCRs). 
Recently, GPCR-arrestin interactions have been proposed to be necessary for 
activation of G-protein-independent signaling pathways, one of which is the 
activation of mitogen activated protein kinases (MAPKs). To investigate potential 
arrestin-MAPK interactions, we have used a variety of molecular tools including 
the co-expression of the individual domains of arrestin with single components of 
the c-Raf1-MEK1-ERK2 signaling cascade. We found that non-visual arrestins 
bind all three kinases, assembling c-Raf1, MEK1, and ERK2 along their short 
axis, with each kinase directly interacting with both domains.  
To further investigate the interactions between arrestins and MAPK, we 
used alanine-scanning mutagenesis of residues on the non-receptor-binding 
surface of arrestin that are conserved between arrestin-2 and arrestin-3. We 
found that the substitution of arginine 307 with an alanine significantly reduced 
arrestin-2 binding to c-Raf1, whereas the interactions of this mutant with active 
phosphorylated receptors and the downstream kinases MEK1 and ERK2 were 
not affected. In contrast to wild type arrestin-2, Arg307Ala mutant failed to rescue 
arrestin-dependent ERK1/2 activation in arrestin-2/3 knockout MEFs. 
Interestingly, alanine substitution of the homologous arrestin-3 residue (lysine 
308) did not significantly affect c-Raf1 binding or its ability to promote ERK1/2 
activation. Together, these findings suggest that the two non-visual arrestins 
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perform the same function via distinct molecular mechanisms. To further 
elucidate arrestin-MAPK interactions, we performed in vitro binding assays using 
pure proteins, and demonstrated that ERK2 directly binds free arrestin-2 and 
arrestin-3, as well as receptor-associated arrestin-1, arrestin-2, and arrestin-3. 
We have also shown that the arrestin-2 and arrestin-3 association with beta2-
adrenergic receptors (β2ARs) significantly enhances ERK2 binding, yet has 
virtually no effect upon arrestins interactions with the upstream kinases c-Raf1 
and MEK1.  
Arrestins exist in three conformational states: free, receptor-bound, and 
microtubule (MT)-bound. Using conformationally biased arrestin mutants, we 
found that ERK2 prefers two conformations: MT-bound, mimicked by 
“constitutively inactive” arrestin-∆7, and receptor-bound, mimicked by “pre-
activated” arrestin-3A. Both mutants were able to rescue arrestin-mediated 
ERK1/2 activation in arrestin-2/3 double knockout fibroblasts. Lastly, we found 
that the arrestin-2 interaction with c-Raf1 is enhanced by receptor binding, 
whereas the interaction between arrestin-3 and c-Raf1 is not, thus suggesting 
that the two non-visual arrestins execute similar functions via diverse 
mechanisms. 
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CHAPTER I 
 
INTRODUCTION 
 
G protein-coupled receptors 
 G Protein-Coupled Receptors (GPCRs), a family of seven transmembrane 
domain proteins, are the most abundant cell surface receptors in the human 
genome (Lander, Linton et al. 2001; Venter, Adams et al. 2001). They are 
essential for many cellular functions (Wess 1998) and are involved in numerous 
physiological and pathological processes (Lombardi, Kavelaars et al. 2002; 
Rockman, Koch et al. 2002; Premont 2005).  
More than 200 of the GPCRs identified have known functions, and when 
they are defective, or have faulty interactions with G-proteins, diseases such as 
breast cancer, congestive heart failure and blindness, to name a few, may result 
(Muller, Homey et al. 2001; Metaye, Gibelin et al. 2005). More than 60% of all 
prescribed drugs target GPCRs (Papasaikas, Bagos et al. 2003; Overington, Al-
Lazikani et al. 2006). Despite the significant level of research focused upon 
further elucidating biological functions of GPCRs, our understanding is still quite 
limited, as we have crystal structures of very few GPCRs. These include 
rhodopsin in the inactive (Palczewski, Kumasaka et al. 2000; Li, Edwards et al. 
2004; Standfuss, Xie et al. 2007) and active (Choe, Kim et al. ; Standfuss, 
Edwards et al. ; Park, Scheerer et al. 2008; Scheerer, Park et al. 2008) state, 
beta-2 adrenergic receptor (β2AR) (Kobilka and Schertler 2008), beta-1 
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adrenergic receptor (Moukhametzianov, Warne et al. ; Warne, Moukhametzianov 
et al. ; Warne, Serrano-Vega et al. 2008), H1 histamine (Shimamura, Shiroishi et 
al.), A2A adenosine (Xu, Wu et al. ; Jaakola, Griffith et al. 2008), D3 dopamine 
(Chien, Liu et al.), and CRXR4 chemokine receptor (Wu, Chien et al.). 
Characterization of the remaining GPCR structures has therefore relied upon 
sequence homology alignments and mutagenesis studies (Hjorth, Schambye et 
al. 1994; Ohyama, Yamano et al. 1995). 
  All GPCRs span the cell membrane seven times with interconnecting 
intracellular and extracellular loops, and possess an extracellular amino-terminus 
(N-terminus) and an intracellular carboxyl-terminus (C-terminus) (Baldwin, 
Schertler et al. 1997). GPCRs range in size from 40-60 kDa and have been 
classified into five classes (Figure 1). Class A includes the largest group of 
GPCRs, and is also referred as rhodopsin-like. Examples of this class include 
beta-adrenergic, rhodopsin, muscarinic and dopamine receptors. Class B, 
secretin-like, is characterized by a large extracellular N-terminus. Typical 
examples from this class are glucagon, the corticotropin-releasing factor receptor 
and the parathyroid hormone receptor (Gurevich and Gurevich 2008). The third 
class of GPCRs, class C, includes the metabotropic glutamate as well as the 
calcium-sensing receptors.  
GPCRs are stimulated by interactions with extracellular signals such as 
drugs, hormones, photons, ions, peptides and even proteins. Their interactions 
induce a conformational change in the protein structure of GPCRs allowing for 
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transduction of cellular signals to secondary signaling components via G-
proteins. 
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Figure 1. GPCR classification. 
GPCRs are classified, based on amino-acids comparison, into five classes:  
Class A ‘rhodopsin-like”; class B ‘secretin-like’; class C ‘metabotropic 
glutamate/pheromone’; class D ‘fungal pheromone’; and class E, cAMP 
receptors. From (Bockaert and Pin 1999) 
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GPCR/G-protein interactions 
Mutagenesis studies have been very useful in the identification of the 
GPCR amino acids responsible for G-protein selectivity and interactions (Conklin, 
Farfel et al. 1993; Wess 1998). G-proteins, which are heterotrimeric proteins, 
consist of alpha (Gα), beta (Gβ) and gamma (Gγ) subunits. There are 20 isoforms 
of Gα, 6 isoforms of Gβ and 11 isoforms of Gγ. Based upon sequence homology, 
Gαs are divided into four families: Gαs, Gαi, Gαq and Gα12/13. Heterotrimeric G 
proteins are classified based upon Gα subunit characteristics (Lefkowitz 1998). 
The Gαs family members stimulate adenylyl cyclase, which results in increased 
production of cyclic AMP (cAMP), whereas Gαi members inhibit adenylyl cyclase 
activation. Members of the Gαq family stimulate phospholipase Cγ (PLCγ), which 
results in the cleavage of phosphoinositol bisphosphate and the resultant 
production of diacylglycerol (DAG) and inositol triphosphate ultimately leads to an 
increase in intracellular calcium and PKC activation. The signaling effectors of 
the Gα12/13 family have not been well characterized (Gether and Kobilka 1998). 
The interactions between GPCR and G-protein are mediated via the C-terminus 
of the Gα subunit, assisted by the Gα N-terminus and several other elements, as 
revealed by the recent crystal structure of β2AR-Gs complex (Rasmussen, 
Devree et al.). Activation of GPCRs induces exchange of guanosine diphosphate 
(GDP) for guanosine triphosphate (GTP) on the Gα subunit, resulting in its 
dissociation from both the receptor and the G-beta-gamma dimer (Gβγ). The Gα 
subunit, as well as the Gβγ dimer, amplify and transduce signals within the cell by 
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modulating the activity of effector molecules (Lefkowitz 1998; Lefkowitz and 
Shenoy 2005). Subsequently, signaling initiated by G-proteins is terminated by 
the intrinsic GTPase activity of Gα, which results in re-assembly of the G-protein 
heterotrimer. This process is accelerated by regulators of G-protein signaling 
(RGS proteins) (Willars 2006). Following activation of G-protein signaling 
cascades, a class of serine/threonine kinases leads to “uncoupling” of the G-
protein from the receptor. This class includes the second-messenger-regulated 
kinases, PKA (protein kinase A) and PKC (protein kinase C). These kinases 
phosphorylate both active and inactive GPCRs resulting in “heterologous” 
desensitization (Lefkowitz 1998), whereas GPCRs that have been agonist-
stimulated are phosphorylated by G protein-coupled receptor kinases (GRKs) 
and undergo “homologous” desensitization (Figure 2).  
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Figure 2. Model of GPCR activation and arrestin recruitment. 
(A) Heterotrimeric inactive G-proteins couple to the ligand-activated GPCR. (B) 
The activated receptor causes an exchange of GDP for GTP, (C) which results in 
dissociation of the G-protein trimer. (D) Subsequent phosphorylation of the 
GPCR by GRK induces arrestin recruitment, followed by the release of the C-
terminal tail and interaction with adaptor protein-2 and clathrin.    
 
A B 
C D 
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The role of G-protein coupled receptor kinases (GRKs) 
Agonist-induced β2AR phosphorylation was found to occur in cells lacking cyclic 
adenosine monophosphate (cAMP) dependent protein kinases (Strasser, Sibley 
et al. 1986). The enzyme responsible was purified and named beta-adrenergic 
receptor kinase (Benovic, Strasser et al. 1986; Benovic, Mayor et al. 1987). It 
was not until later that the ‘beta-adrenergic receptor kinase’ was named ‘G-
protein coupled receptor kinase 2’ (GRK2). Identification of the remaining GRK 
family members followed the cloning of GRK2 cDNA (Benovic, DeBlasi et al. 
1989) and rhodopsin kinase, also known as GRK1, (Lorenz, Inglese et al. 1991). 
Subsequently, all other mammalian GRKs were identified via cloning (Benovic, 
Onorato et al. 1991; Kunapuli and Benovic 1993; Premont, Koch et al. 1994), and 
subdivided into three main groups, based on sequence homology: 1) Rhodopsin 
kinase, or the visual GRK subfamily (GRK1 and GRK7); 2) The β-adrenergic 
receptor kinase subfamily (GRK2 and GRK3); 3) The GRK4 subfamily (GRK4, 
GRK5 and GRK6).  
The current models of GRK function suggest that following activation by 
an agonist, GPCRs are phosphorylated exclusively at serine and threonine 
residues. This results in a decrease in the affinity of GPCRs for G-proteins and 
an increase in their affinity for arrestins (Fig.2). 
 
Arrestin structure and function 
Arrestins are proteins ubiquitously expressed in cells and tissues, and function in 
the desensitization of most GPCRs. Non-visual arrestins (arrestin-2 and arrestin-
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3) were discovered in the late 1980s and early 1990s, from the observation that 
addition of visual arrestin  enhances phosphorylation-dependent reduction of G 
protein activation by β2AR (Lohse, Benovic et al. 1990). This event suggested 
that proteins homologous to visual arrestin could exist in non-visual systems. 
Molecular cloning confirmed the existence of two arrestin isoforms: beta arrestin-
1 (arrestin-2) and beta arrestin-2 (arrestin-3)(Attramadal, Arriza et al. 1992; 
Sterne-Marr, Gurevich et al. 1993). The four mammalian arrestins are highly 
homologous, with major differences found in the C-termini, where the visual 
arrestins appear to lack the clathrin binding site. Both arrestin-2 or arrestin-3 
knockout mice possess phenotypes comparable to their wild type littermates 
(Bohn, Lefkowitz et al. 1999), but are deficient in blood pressure regulation 
(Conner, Mathier et al. 1997). On the other hand, the arrestin-2/3 double-
knockout was reported to be embryonic lethal (Kohout, Lin et al. 2001). These 
data suggest that non-visual arrestins can functionally substitute for one another.  
The structures of arrestin-2 and arrestin-3 have been solved by X-ray 
crystallography (Zhan, Gimenez et al. ; Han, Gurevich et al. 2001). Three-
dimensional structures show that arrestins consist of two groups of beta-sheets, 
referred to as the N-domain and the C-domains, connected by the inter-domain 
hinge and the C-tail (Figure 3).  
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Figure 3. Secondary structure of Arrestin-2  
Structural diagram of arrestin-2 basal conformation, showing that arrestins are 
made up of mainly beta-sheets and one short alpha-helix. N-domain and C-
domain are connected by a hinge, as shown. Adapted from (Han, Gurevich et al. 
2001) 
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Localization of receptor binding elements on the concave sides of both 
domains of arrestin suggests that their movement towards each other, bringing 
all elements in close proximity with the receptor, is a necessary conformational 
rearrangement required for arrestin-receptor binding. Movement of arrestin 
domains toward each other is limited by  the length of the inter-domain connector 
referred to as  the “hinge” (Fig.3) (Vishnivetskiy, Hirsch et al. 2002).  This hinge is 
12 residues long and increasing deletions have been shown to progressively 
reduce the ability of arrestin binding to the receptor.  
Upon binding to the receptor, the C-tail of arrestin is released upon 
destabilization of the three-element interacting region (Fig. 4A) and the polar core 
(Fig. 4B). The three-element interaction is a group of three hydrophobic residues 
(Val11, Ile12, and Phe13) which interact with α-helix I and arrestin C-tail (Hirsch, 
Schubert et al. 1999). Phosphorylation-independent mutants result from the 
disruption of this three-element interaction (Gurevich 1998; Vishnivetskiy, 
Schubert et al. 2000). Extensive mutagenesis studies have been performed on 
all five residues (Arg175, Asp30, Asp296, Asp303 and Arg382) in the “polar core” 
and have shown that Asp296 is the most important negatively charged partner of 
Arg175 (Vishnivetskiy, Paz et al. 1999). Also, the charge reversal of Arg175 (to 
glutamate) has been shown to confer the ability of arrestin to bind non-
phosphorylated GPCRs (Vishnivetskiy, Paz et al. 1999).  
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Figure 4. Arrestin polar core and three element interaction 
A. Hydrophobic three-element interaction with residues 375–377 (Phe-Val-Phe) 
of the C-tail and leucines 103, 107, and 111 of the α-helix I. B. hydrogen bonds 
between Arg175, Asp 30, Asp296, Asp303 and Arg382 stabilize the polar core as 
shown. Adapted from (Vishnivetskiy, Paz et al. 1999; Vishnivetskiy, Schubert et 
al. 2000; Hanson and Gurevich 2006) 
 
A B 
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Taken together, these studies suggest that the binding of arrestin to the 
phosphorylated receptor results in the disruption of the Arg175-Asp296 
interaction, destabilization of the three-element interaction and thus results in an 
increase in the affinity of arrestin binding to the receptor. Subsequently, the 
release of the arrestin C-terminal tail allows for the interaction of arrestin with the 
accessory proteins clathrin and adaptor protein 2 (AP-2), ultimately driving 
internalization of GPCR/arrestin complexes via clathrin coated pits (Goodman, 
Krupnick et al. 1996; Laporte, Oakley et al. 1999; van Koppen 2001). 
Finally, following internalization, the receptor/arrestin complex has one of 
two fates: 1) degradation or 2) recycling. The GPCR/arrestin complex has been 
shown to scaffold MAPK signaling cascades including the extracellular signal-
regulated kinase 1/2 (ERK1/2) (Luttrell, Roudabush et al. 2001), c-jun N-terminal 
kinase 3 (JNK3) (McDonald, Chow et al. 2000) and p38 (Bruchas, Macey et al. 
2006).  
 
Mitogen Activated Protein Kinases (MAPKs) overview 
 MAPKs are serine/threonine specific protein kinases which are 
evolutionary conserved among eukaryotes and play an important role in the 
transduction of signals from the extracellular environment. Five distinct MAPK 
families have been identified in mammals (Schaeffer and Weber 1999), and the 
kinases that have been widely studied and characterized include: a) ERK1/2, b) 
JNK and c) p38. The c-jun N-terminal kinases, also known as stress-activated 
protein kinases (SAPKs), and p38 MAPKs are primarily activated by various 
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stress stimuli, including heat shock, cytokines and ultraviolet (UV) light, and are 
key to cell differentiation and apoptosis. ERK1/2 proteins have been extensively 
studied and are the major transducers of growth factor stimulation. ERK1/2 are 
both known to regulate cell proliferation and cell differentiation. MAPK modules 
are composed of three kinases: a MAPKKK, responsible for the phosphorylation 
and activation of a MAPKK, which, in turn, phosphorylates and activates a 
MAPK. The ERK1/2 cascade is composed of c-Raf1, MEK1 and ERK1/2, where 
ERK is a MAPK, MEK (MAPK/ERK kinase) is a MAPKK and Raf is a MAPKKK. 
Once activated c-Raf1 phosphorylates and activates the dual specificity kinase 
MEK. The interaction between c-Raf1 and MEK is dependent on a proline-rich 
sequence in MEK (Catling, Schaeffer et al. 1995). While A-Raf has been shown 
to activate only MEK1 (Wu, Noh et al. 1996), c-Raf1 can activate both isoforms of 
MEK, MEK1 and MEK2, which, are both capable of phosphorylating tyrosine and 
threonine residues on ERK1 and ERK2. The serine/threonine kinases ERK1/2, 
once activated, can either translocate to the nucleus and activate transcription 
factors via phosphorylation, (Schaeffer and Weber 1999) including Elk-1 and 
SAP1, or remain in the cytoplasm and phosphorylate other substrates. One 
common feature of all MAPK modules is that they need to be organized by 
scaffolding proteins in order to: allow the precise regulation of their signaling; 
prevent their activation by irrelevant stimuli; and provide spatial and temporal 
control of signaling. 
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Arrestin-dependent signaling 
The first indication that arrestins could function as signaling adapters 
arose from studies of receptor internalization defective systems (Luttrell, 
Ferguson et al. 1999) and arrestin-dependent c-Src recruitment to GPCRs 
(Luttrell, Ferguson et al. 1999; DeFea, Vaughn et al. 2000; Miller, Maudsley et al. 
2000). Mutations of the regions in arrestin that bind SH3 domains (Milano, Pace 
et al. 2002) were reported to: decrease c-Src binding upon receptor activation; 
and decrease ERK1/2 phosphorylation; suggesting that arrestin binding to c-Src 
is critical for the activation of ERK1/2. Recent studies have shown that ERK1/2 
activation via stimulation of the β2-AR or the AT1AR receptor exhibited two 
individual phases (Shenoy and Lefkowitz 2005; Shenoy, Drake et al. 2006); an 
early, G-protein dependent phase peaking at around 5 minutes, and a later 
phase (20min) which was thought to be arrestin dependent. To demonstrate that 
the second phase was arrestin dependent, the authors inhibited G protein 
activation using pertussis toxin and they observed a decrease in the early 
activation phase of ERK1/2. Upon knockdown of arrestins using siRNA, the 
second phase was found to be decreased.  
 The activation of the ERK1/2 cascade by G-proteins is thought to induce 
the translocation of ERK1/2 to the nucleus and initiate transcription of a variety of 
transcription factors (Tohgo, Pierce et al. 2002). In contrast, when ERK1/2 are 
activated in an arrestin-dependent manner, ERK1/2 accumulate in the cytosol, 
where they can activate different effectors and possibly produce different 
physiological effects than those achieved by G proteins. Finally, the arrestin-2 C-
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terminal serine 412 is known to be constitutively phosphorylated by ERK2. 
Phosphorylation of this residue has been reported to decrease the affinity of 
arrestin for clathrin and thereby inhibit receptor internalization (Lin, Miller et al. 
1999). The biological function of arrestins, in terms of signal transduction, are 
likely much broader than we currently know. Here, we have explored the mode of 
interactions of arrestins and MAPK as well as the mechanisms by which these 
kinases are ultimately activated. Arrestin signaling represents a potentially new 
therapeutic target for diseases, and should therefore be further elucidated. 
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CHAPTER II 
 
ARRANGEMENT OF MAPKs ON NON-VISUAL ARRESTINS. 
 
INTRODUCTION 
Arrestins are a family of proteins that serve as regulators of G-protein coupled 
receptors (GPCRs) signaling. Recently it has been proposed that GPCRs 
coupled to arrestins activate signaling pathways that are G-protein independent. 
For instance, the activation of the mitogen activated protein kinases (MAPKs) 
such as extracellular signal-regulated kinase ERK1/2, c-Jun N-terminal kinase 3 
(JNK3) and p38 as well as Src has been shown to be arrestin dependent (Luttrell 
and Lefkowitz 2002; Perry and Lefkowitz 2002; Sun, Cheng et al. 2002). These 
kinase cascades have been shown to form complexes with both arrestins and 
GPCRs (DeFea, Zalevsky et al. 2000; Miller and Lefkowitz 2001; Hall and 
Lefkowitz 2002). The ERK1/2 signaling pathway consists of three kinases: a 
MAPKKK (RAF), which phosphorylates a MAPKK (MEK) which will sequentially 
phosphorylate a MAPK (ERK1/2) (Macdonald, Crews et al. 1993). The JNK3 
pathway also works on sequential phosphorylation of a MAPKKK (ASK), a 
MAPKK (MKK4) and a MAPK (JNK3) (Ichijo 1999). ERK1/2 activation occurs on 
both a tyrosine and a threonine residue (Boulton, Nye et al. 1991), within the 
activation loop, by upstream kinases (MEK1/2). ERKs activation by GPCR can 
be a Ras-dependent event or, depending on the receptor type, can be mediated 
by PKC, some tyrosine kinases (i.e. Src) or by direct interaction with arrestins. 
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ERK1/2 activation mediated by arrestin will likely lead to different physiological 
consequences than those achieved by G protein activation. ERK1/2 activation by 
G proteins leads to the accumulation of these kinases (ERKs) in the nucleus, 
where they can phosphorylate and activate various transcription factors (Pierce, 
Luttrell et al. 2001). In contrast, when ERK activation is promoted by arrestins, 
ERK is found mainly in cytoplasmic compartments (Tohgo, Pierce et al. 2002) of 
the cell where it may phosphorylate non-nuclear substrates. Several GPCRs 
have been shown to activate ERKs via their interactions with arrestins. Examples 
include the angiotensin type 1A receptor (AT1AR) (Luttrell, Roudabush et al. 
2001) and the protease-activated receptor-2 (PAR-2) (DeFea, Zalevsky et al. 
2000). In general, MAPK activation serves to control many cellular functions 
including cell proliferation, differentiation and apoptosis and can be activated by 
many extracellular signals such as growth factors and hormones. In order to 
determine the interactions of arrestin2 and arrestin3 and their individual domains 
with the components of the c-Raf-1-MEK1-ERK2 cascade we utilized co-
immunoprecipitation and found that both arrestin domains interact with c-Raf-1, 
MEK1 and ERK2. 
 
METHODS 
Cell Culture and Transient Transfection  
COS-7 African green monkey cells were maintained in Dulbecco's 
modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine 
serum plus penicillin and streptomycin at 37 °C in a humidified incubator with 5% 
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CO2. The cells were plated at 80-90% confluence and transfected with the 
indicated plasmids using Lipofectamine™ 2000 (Invitrogen; Carlsbad, CA), 
according to the manufacturers protocol (3 µL of Lipofectamine™ 2000 per 1 µg 
of DNA). 24 hours post-transfection, cells were serum-starved and lysed with 
lysis buffer (50mM Tris-HCl pH 7.5, 2mM EDTA, 250mM NaCl, 10% glycerol, 
0.5% Nonidet P-40, 1mM NaVO3, 10mM N-ethylmaleimide, benzamidine and 
phenylmethylsulfonylfluoride) on ice for 20 minutes. Cell debris were pelleted by 
centrifugation for 10 minuntes at 10,000 x g. Arrestins and MAPKs were then 
immunoprecipitated as described below.  
 
Immunoprecipitation 
In experiments involving ERK2, prior to lysis the cells were treated with 1 
mM cross-linking reagent dithiobis (succinimidyl propionate) (DSP; Pierce) for 30 
min followed by 2 mM Tris-HCl, pH 7.5, for 15 min at room temperature. After 
centrifugation, supernatants were precleared by 30 µl of protein G-agarose. 
Then, 600 µl of supernatant was incubated with primary antibodies for 2 hours 
followed by the addition of 12 µl of protein-G agarose beads for 2 hours or 
overnight. The beads were washed three times with 1 ml of lysis buffer, and the 
proteins were eluted with 50 µl of sample buffer, boiled for 5 min, and analyzed 
by Western blot. 
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Western Blot 
The proteins were resolved by 10% SDS-PAGE and transferred to 
polyvinylidene difluoride membrane (Millipore, Bedford, MA). Mouse monoclonal 
antibodies against FLAG (Sigma), HA (Sigma), GFP (Clontech), and phospho-
JNK (Cell Signaling Technology Inc.) were used at 1:1000 or 1:2000 dilution 
followed by horseradish peroxidase-conjugated anti-mouse secondary antibody. 
Protein bands were detected by enhanced chemiluminescence (ECL, Pierce) 
followed by exposure to x-ray film. Immunoblots were quantified using 
QuantityOne software (Bio-Rad Laboratories). 
 
Statistical Analysis 
Quantitative data from at least three experiments were analyzed by one-
way analysis of variance with arrestin as a main factor (with Bonferroni-Dunn 
correction for multiple comparisons).  
 
RESULTS 
The Molecular Interactions Mediating Arrestin-dependent Assembly of the 
ERK Signaling Module 
To determine the orientation of c-Raf-1, MEK1, and ERK2 on non-visual 
arrestins, we co-expressed these kinases with arrestin2, arrestin3, and their 
separated N- and C- terminal domains in COS-7 cells. We tested the ability of 
arrestins to co-immunoprecipitate with the kinases, as well as the ability of c-
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Raf1, MEK1, and ERK2 to co-immunoprecipitate arrestins and their separately 
expressed domains (Fig. 5). MEK1 (Fig. 5B) and cRaf-1 (Fig. 5C) were readily 
detectable in complex with both full-length arrestins. Both kinases demonstrated 
comparable binding to arrestin2, arrestin3, and individual domains. In contrast, 
the affinity of the ERK2-arrestin interaction appears to be lower than that of the 
upstream kinases, therefore cross-linking was required for reliable detection of 
the arrestin-ERK2 interaction (Fig. 5A). ERK2 also interacts comparably with 
both nonvisual arrestins and their N- and C- terminal domains (Fig. 5A). 
Collectively, our data demonstrate that each of the three kinases, cRaf-1, MEK1, 
and ERK2, binds equally well to both domains of arrestins.  
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Figure 5. ERK2, MEK1 and cRaf-1 interact with both domains of arrestin2 
and arrestin3. COS-7 cells were transfected with plasmids encoding FLAG-
tagged arrestin2 (A2), arrestin2 N-domain (A2N), arrestin2 C-domain (A2C), 
arrestin3 (A3), arrestin3 N-domain (A3N), or arrestin3 C-domain (A3C). HA-
tagged ERK2, MEK1, and c-Raf1 were co-expressed with indicated FLAG-
tagged arrestins. Arrestins were immunoprecipitated with M2 anti-FLAG 
antibody, and precipitates were probed for ERK2-HA (A), MEK1-HA (B) or c-Raf-
1-HA (C). Alternatively, individually expressed kinases were immunoprecipitated 
with anti-HA antibody, and the precipitates were probed for arrestins using anti-
FLAG antibody (A-C). The relative expression of each protein was confirmed by 
immunoblotting cell lysates (shown in the two lower blots in each panel). 
Asterisks, nonspecific band (heavy chain of the antibody). 
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DISCUSSION 
Arrestins have been reported to serve as GPCR activation-dependent scaffolds 
(Shenoy and Lefkowitz 2003), but the molecular organization of the arrestin-
MAPKs complex has not been elucidated. Therefore, we decided to investigate 
the assembly of the c-Raf-1-MEK1-ERK1/2 signaling cascade on non-visual 
arrestin proteins. Interestingly, we found that both arrestin domains interact with 
c-Raf-1, MEK1 and ERK2, but contrary to the ASK1-MKK4-JNK3 cascade (Song, 
Coffa et al. 2009), where the binding of each kinase is robust, in the c-Raf1-
MEK1-ERK2 cascade c-Raf1 and MEK1 demonstrate strong binding, whereas 
arrestins interaction with ERK2 is very weak (Fig. 5). The subtle differences 
observed between the two cascades suggest that, JNK3 is more likely to remain 
in the complex and to phosphorylate cytoplasmic substrates than ERK2 when 
arrestin is not bound to a receptor. Based on our data, we propose a model of 
arrestin-dependent assembly of the MAPK signaling module, in which, arrestins 
bind all three kinases, assembling c-Raf1, MEK1, and ERK2 along its short axis, 
with each kinase directly interacting with both domains of arrestin (Fig. 6). The 
members of this MAPK cascade assemble on the arrestin molecule similarly to 
the components of the ASK1-MKK4-JNK3 signaling module (Song, Coffa et al. 
2009). Therefore, this appears to be a universal mode of assembly of the three 
kinases on arrestin scaffolds. 
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Figure 6. The model of MAPK signaling module organized by arrestin.  
The three-dimensional model representing how arrestins assemble MAP kinases 
is shown as front (Fig.6A) and side views (Fig.6B). Arrestin (purple) is shown as 
an elongated two-domain molecule. All three kinases are shown to interact 
directly with both arrestin domains. From (Song, Coffa et al. 2009).  
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CHAPTER III 
 
A SINGLE MUTATION IN ARRESTIN-2 PREVENTS ERK1/2 ACTIVATION BY 
REDUCING C-RAF1 BINDING. 
 
INTRODUCTION 
Arrestins regulate the signaling and trafficking of G protein-coupled 
receptors (GPCRs). GPCRs complex both non-visual arrestins, channeling 
signaling to G protein-independent pathways, one of which is the activation of 
extracellular signal regulated kinase 1/2 (ERK1/2).  
The first indication that arrestins function as signaling adapters came from 
the studies of arrestin-dependent c-Src recruitment to GPCRs, which resulted in 
the activation of ERK1/2 (Luttrell, Ferguson et al. 1999; DeFea, Vaughn et al. 
2000; Miller, Maudsley et al. 2000). Subsequently, arrestin2 and arrestin3 were 
shown to scaffold the JNK3 (McDonald, Chow et al. 2000), ERK1/2 (DeFea, 
Zalevsky et al. 2000; Luttrell, Roudabush et al. 2001), and p38 (Sun, Cheng et al. 
2002; Bruchas, Macey et al. 2006) cascades. Despite the fact that arrestins play 
important roles in regulating MAPK pathways, the mechanism by which arrestins 
assemble MAP kinases into a signaling complex is not clear. Arrestins facilitate 
the activation of JNK3 (McDonald, Chow et al. 2000), ERK1/2 (Luttrell, 
Roudabush et al. 2001), and p38 (Bruchas, Macey et al. 2006). Free and 
receptor-bound arrestins differentially interact with MAPKs and other signaling 
proteins (McDonald, Chow et al. 2000; Luttrell, Roudabush et al. 2001; Miller, 
   
26 
McDonald et al. 2001; Bruchas, Macey et al. 2006; Song, Raman et al. 2006). 
Here we focused on the c-Raf1-MEK1-ERK1/2 cascade, in which all three 
kinases bind arrestin-2 and arrestin-3 (Song, Coffa et al. 2009). ERK1/2 
phosphorylation is facilitated by both non-visual arrestins and is contingent on 
GPCR activation (Luttrell, Roudabush et al. 2001). These data suggest that: a) 
the elements conserved between arrestin-2 and -3 play key roles; and b) the 
well-defined surface occupied by bound receptor (Ohguro, Palczewski et al. 
1994; Pulvermuller, Schroder et al. 2000; Vishnivetskiy, Hosey et al. 2004; 
Hanson, Francis et al. 2006; Hanson and Gurevich 2006; Vishnivetskiy, Gimenez 
et al. 2011; Zhan, Gimenez et al. 2011) is not involved in the interactions with 
ERK or upstream kinases. Therefore, we decided to perform alanine-scanning 
mutagenesis of the conserved residues on the non-receptor-binding surface of 
arrestin-2 and to compare the ability of wild type (WT) and mutant arrestin-2 to 
bind receptor, c-Raf1, MEK1, ERK2, and promote ERK1/2 phosphorylation in 
COS-7 and arrestin double knock out (DKO) mouse embryonic fibroblast (MEF) 
cells.  
We found that the Arg307Ala mutation significantly reduced arrestin-2 
binding to c-Raf1, whereas the binding of the mutant arrestin to active 
phosphorylated receptor and downstream kinases MEK1 and ERK2 was not 
affected. In contrast to wild type arrestin-2, the Arg307Ala mutant failed to rescue 
arrestin-dependent ERK1/2 activation via β2-adrenergic receptor in arrestin-2/3 
double knockout mouse embryonic fibroblasts. Thus, Arg307 appears to play a 
specific role in the ability of arrestin-2 to bind c-Raf1, and is indispensable in the 
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productive scaffolding of c-Raf1-MEK1-ERK1/2 signaling cascade. Arg307Ala 
mutation specifically eliminates arrestin-2 signaling through ERK, which makes 
arrestin-2-Arg307Ala the first signaling-biased arrestin mutant constructed. The 
crystal structure reveals that the Lys308 residue of the side chain of homologous 
arrestin-3 points in a different direction. Alanine substitution of Lys308 does not 
significantly affect c-Raf1 binding to arrestin-3 and its ability to promote ERK1/2 
activation, suggesting that the two non-visual arrestins perform the same function 
via distinct molecular mechanisms.  
 
METHODS 
Site-directed mutagenesis 
Site-directed mutagenesis by PCR (Supplemental Table S1) was 
performed using pGEM2-based transcription vectors encoding WT bovine 
arrestin-2 and arrestin-3 with unique restriction sites engineered and previously 
described (Vishnivetskiy, Hosey et al. 2004; Vishnivetskiy, Gimenez et al. 2011). 
All constructs were verified by dideoxy sequencing. The coding sequences were 
excised with EcoR I and Hind III and subcloned into pcDNA3 for expression in 
cultured mammalian cells and into pFB vector for retrovirus production.  
 
In vitro transcription, translation, and evaluation of protein stability  
Plasmids were linearized using a unique Hind III site downstream of the 
coding sequence. In vitro transcription and translation were performed as 
previously described (Gurevich and Benovic 1992; Gurevich and Benovic 1993). 
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All arrestin proteins were labeled by incorporation of [3H]leucine and [14C]leucine 
with a specific activity of the mix of 1.5-3 Ci/mmol, resulting in the specific activity 
of arrestin proteins within the range of 66-85 Ci/mmol (150-230 dpm/fmol). The 
translation of every mutant used in this study produced a singly labeled protein 
band with the expected mobility on SDS-PAGE. Two parameters were used for 
the assessment of mutant relative stability, as described (Gurevich 1998): its 
yield multiplied by the percentage of the protein remaining in the supernatant 
after incubation for 10 minutes at 37oC followed by centrifugation (Supplemental 
Table S2). 
 
Receptor binding assay 
The binding to light-activated phosphorylated rhodopsin (P-Rh*) was 
performed, as previously described (Gurevich, Dion et al. 1995). Briefly, 
translated radiolabeled arrestins (50 fmol) were incubated in 50 mM Tris-HCl, pH 
7.5, 0.5 mM MgCl2, 1.5 mM dithiothreitol, 1 mM EGTA, 50 mM potassium acetate 
with 7.5 pmol (0.3 µg) of P-Rh* in a final volume of 50 µl for 5 min at 37oC in 
room light, and then cooled on ice. Bound and free arrestins were separated by 
size-exclusion chromatography on 2-ml columns of Sepharose 2B-CL 
equilibrated with 10 mM Tris-HCl, pH 7.5, 100 mM NaCl, at 4°C. Rhodopsin-
bound arrestins (eluted with receptor-containing membranes in the void volume 
between 0.5 and 1.1 ml) were quantified by liquid scintillation counting. 
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Co-immunoprecipitation and Western blotting 
Monkey kidney COS-7 cells were transfected with the indicated plasmids 
using Lipofectamine™ 2000 (Invitrogen; Carlsbad, CA), according to the 
manufacturers protocol (3 µL of Lipofectamine™ 2000 per 1 µg of DNA). 24 
hours post-transfection, cells were serum-starved and lysed with lysis buffer 
(50mM Tris, 2mM EDTA, 250mM NaCl, 10% glycerol, 0.5% Nonidet P-40, 1mM 
NaVO3, 10mM N-ethylmaleimide, benzamidine and phenylmethylsulfonylfluoride) 
on ice for 20 minutes. Cell debris were pelleted by centrifugation for 10 minuntes 
at 10,000 x g. Lysates were precleared with 30 µl of protein G agarose, followed 
by incubation with a rabbit anti FLAG antibody for 2 hours and by the addition of 
30 µl of protein G agarose beads for 2 hours. The beads were then washed 3 
times with lysis buffer, and bound proteins were eluted with Laemmli SDS buffer. 
In experiments involving ERK2, prior to lysis the cells were treated with 1 mM 
cross-linking reagent dithiobis(succinimidyl propionate) (DSP; Pierce) for 30 
minutes followed by 2 mM Tris-HCl, pH 7.5, for 15 minutes at room temperature. 
The proteins were separated by SDS PAGE (10%) and transferred to 
polyvinylidene difluoride membrane (Millipore, Bedford, MA). Blots were 
incubated with primary antibodies from Cell Signaling (mouse anti-HA (6E2) mAb 
#2367, 1:1500; mouse anti-p44/42 ERK1/2 (L34F12) mAb #4696, 1:1000; and 
mouse anti-p44/42 phospho-ERK1/2 (T202/Y204), (E10) mAb #9106S, 1:1000), 
or Sigma (mouse anti-FLAG M2, #F3165, 1:1500; rabbit anti-FLAG  #F7425), 
followed by anti-mouse horseradish peroxidase-conjugated secondary antibodies 
from Jackson ImmunoResearch. Protein bands were visualized by enhanced 
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chemiluminescence (ECL, Pierce) followed by exposure to X-ray film. The bands 
were quantified using VersaDoc with QuantityOne software (Bio-Rad 
Laboratories). 
 
Arrestin-dependent ERK activation 
For the production of retroviruses, human embryonic kidney (HEK) 293T 
cells were transfected using Lipofectamine™ 2000 (Invitrogen; Carlsbad, CA), 
according to the manufacturer’s protocol (3 µL of Lipofectamine™ 2000 per 1 µg 
of DNA) with the following constructs: pVPack-GP (Stratagene, 217566), pVack-
VSV-G (Stratagene, 217567), together with pFB-arrestin-2, pFB-arrestin-2-
Arg307Ala, pFB-arrestin-3, pFB arrestin-3-K308A, or pFB-GFP. 24-48 hours 
post-transfection, media containing the virus produced by HEK293T cells was 
collected and used to infect arrestin-2/3 double knockout mouse embryonic 
fibroblasts (MEFs) (a generous gift of Dr. R. J. Lefkowitz, Duke University) 
(Kohout, Lin et al. 2001). Fresh virus-containing media was used daily for a total 
of 3 days. Then MEFs were serum starved for 2 hours and subsequently treated 
with 1 µM ICI118551, a biased ligand of β2-adrenergic receptor (β2AR), which is 
an inverse agonist of G protein signaling and an agonist of arrestin recruitment 
(Azzi, Charest et al. 2003), or 10 µM β2AR agonist isoproterenol for 10 minutes 
at 37oC. MEFs were harvested and lysed in 50mM Tris, 2mM EDTA, 100mM 
NaCl, 1% Nonidet P-40, supplemented with protease (Roche, 04693124001) and 
phosphatase (Roche, 04906845001) inhibitors cocktails on ice for 20 minutes.  
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MATERIALS 
[γ-32P]ATP, [14C]leucine, and [3H]leucine were purchased from Perkin-
Elmer. All restriction enzymes were purchased from New England Biolabs. 
Sepharose 2B and all other chemicals were purchased from sources as 
previously described (Gurevich and Benovic 2000; Vishnivetskiy, Francis et al. 
2010). Rabbit reticulocyte lysate was purchased from Ambion, SP6 RNA 
polymerase was prepared as described (Gurevich 1996). Rhodopsin was 
phosphorylated and regenerated by 11-cis-retinal generously supplied by Dr. R. 
K. Crouch (Medical University of South Carolina, Charleston, SC), as described 
(Vishnivetskiy, Raman et al. 2007). 
 
RESULTS 
Functional characterization of arrestin-2 mutants by binding to rhodopsin 
To identify the arrestin-2 elements involved in the binding of c-Raf1, 
MEK1, and ERK2, we generated 22 mutants in which conserved residues on the 
non-receptor-binding surface of both non-visual arrestins were replaced with 
alanines individually or in groups (Fig. 7, Fig. 8A). Receptor binding is the 
signature function of arrestin proteins, and can be easily tested using direct 
binding assays (Gurevich and Benovic 1993; Gurevich, Dion et al. 1995). Both 
non-visual arrestins demonstrate specific binding to phosphorylated light-
activated rhodopsin (P-Rh*) (Gurevich, Dion et al. 1995; Kovoor, Celver et al. 
1999; Celver, Vishnivetskiy et al. 2002). Therefore, we used binding to P-Rh* as 
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the criterion to select proteins that interacted with the receptor normally. To this 
end, the mutants were expressed in cell-free translation, and their binding to P-
Rh* was compared to that of WT arrestin-2 (Fig. 7, Fig. 8B). Twelve mutants 
showed significantly reduced binding, whereas ten demonstrated normal binding 
to P-Rh. Proteins showing normal binding were selected for subsequent 
experiments.  
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Figure 7. P-Rh* binding of all arrestin-2 mutants.  
A. Arrestin-2 structure (upper panel, side view; lower panel, view from concave 
side of the two domains), with residues mutated in this study highlighted, as 
follows: identical between arrestin-2 and -3 residues, red; replaced by 
conservative substitutions, green. B-H. All arrestin-2 (B-G) and arrestin-3 (H) 
mutants were tested in P-Rh* binding assay. Means + SD of two independent 
experiments performed in duplicate are shown. 
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Figure 8. Ten arrestin-2 mutants retain normal receptor binding. A. Arrestin-
2 structure (Han, Gurevich et al. 2001) viewed from the side (upper image) or 
convex surface (lower image). Residues on the non-receptor-binding side, 
conserved in arrestin-2 and -3 that can be mutated to alanines without affecting 
receptor binding are shown as green CPK models, Arg307 is shown in blue.  B. 
The binding of WT and mutant arrestin-2 to P-Rh*. Means +/- SD of three 
experiments performed in duplicate are shown. ANOVA with Bonferroni post-hoc 
test revealed no statistically significant differences between WT arrestin-2 and 
these mutants. 
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Identification of a c-Raf1-binding residue on arrestin-2  
To compare the binding of WT and mutant arrestin-2 to c-Raf1, MEK1, 
and ERK2 in the cellular context, we transiently co-expressed Flag-tagged 
arrestins with HA-tagged kinases in COS-7 cells (chosen because they express 
very low levels of endogenous arrestins). Arrestins were immunoprecipitated with 
an anti-Flag antibody, and co-immunoprecipitated kinases were detected by 
Western blotting using an anti-HA antibody. We found that nine out of the ten 
mutants bound c-Raf1 essentially as well as WT arrestin-2, whereas the amount 
of c-Raf1 co-immunoprecipitated with arrestin-2-Arg307Ala was found to be 
significantly decreased (Figure 9A). Interestingly, none of the mutations tested 
appeared to affect the binding arrestin-2 to MEK1 (Fig. 9B) or ERK2 (Fig. 9C). 
Thus, the Arg307Ala mutation selectively reduces the arrestin-2 interaction with 
c-Raf1, without affecting the binding to the receptor or downstream kinases. 
Similar to other MAP kinases, c-Raf1 interacts with both domains of arrestin-2 
and arrestin-3 (Song, Coffa et al. 2009), which suggests that its binding site 
includes more than one residue. However, the replacement of multiple residues 
on the putative kinase-binding surface with alanines reduces receptor binding 
(Fig. 7). Therefore, their roles in kinase binding and activation could not be 
assessed by alanine scanning mutagenesis.  
Interestingly, an equivalent residue in arrestin-3, which also promotes 
ERK1/2 activation (Luttrell, Roudabush et al. 2001), is Lys308 (Fig. 10) (Zhan, 
Gimenez et al. 2011), suggesting that a positive charge in this position could be 
important. 
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Figure 9. The binding of c-Raf1, MEK1, and ERK2 to WT and mutant 
arrestin-2. Flag-tagged WT arrestin-2 and indicated mutants were co-expressed 
with HA-tagged c-Raf1, MEK1, or ERK2 in COS-7 cells. Arrestins were 
immunoprecipitated with anti-Flag antibody, and co-immounoprecipitated c-Raf1 
(A), MEK1 (B), or ERK2 (C) were visualized by Western blot with anti-HA 
antibody. The binding of all mutants to MEK1 and ERK2 was not different from 
WT arrestin-2, whereas Arg307Ala mutation significantly decreased the binding 
to c-Raf1. Means + SD of 3-4 independent experiments are shown in bar graphs; 
representative blots are shown below. * p<0.05 
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Figure 10. Arginine 307 is a conformationally variable residue. Arg307 can 
form a long ion pair with Asp29, which bridges the N- and C-domains of arrestin-
2. This interaction is likely weak, as evidenced by the lack of its conservation in 
arrestin-1 (1CF1 shown in yellow), some crystal forms of arrestin-2 (3GDI shown 
in green and 3JSY shown in light green), arrestin-3 (3P2D shown in red), and 
arrestin-4 (1AYR shown in orange), and the multiple orientations observed for the 
loop containing Arg307 in arrestin-2. Note that homologous residue in arrestin-3, 
Lys308, points in an opposite direction. 
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Arrestin-dependent ERK1/2 activation induced by ICI118551 via β2AR 
Next we assessed whether the reduced c-Raf1 binding of the Arg307Ala 
mutant affects its ability to promote receptor-dependent ERK1/2 activation. 
GPCRs activate ERK1/2 via multiple G protein-dependent and independent 
pathways, one of which involves arrestin scaffolding of the c-Raf1-MEK1-ERK1/2 
cascade (Luttrell 2003). Although in some cases the pathways can be 
distinguished by their time course, with rapid phase of ERK1/2 phosphorylation 
largely mediated by the G-protein and the slower phase attributable to arrestins 
(Ahn, Shenoy et al. 2004; Shenoy, Drake et al. 2006). However, in other cases 
both phases appear to be G protein-dependent (Luo, Busillo et al. 2008). An 
inverse agonist of β2AR, ICI118551, that blocks G protein activation, was shown 
to be a biased ligand, acting as an agonist for non-visual arrestins (Azzi, Charest 
et al. 2003). We confirmed this observation by showing that the robust activation 
of endogenous ERK1/2 induced by ICI118551 via endogenous β2AR is readily 
detected in WT MEFs, but completely absent in the arrestin-2/3 double knockout 
(DKO) MEFs (Fig. 11A). Therefore, we used the ability of arrestin expressed in 
DKO MEFs to rescue ICI118551-induced ERK1/2 activation as our readout. We 
found that WT arrestin-2 successfully rescues ERK1/2 activation using 
ICI118551, whereas the Arg307Ala mutant expressed at the same level failed to 
do so (Fig. 11B).  
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Figure 11. Arg307Ala mutant fails to rescue β2AR-mediated ERK activation 
in arrestin-2/3 knockout MEFs. A. WT and arrestin-2/3 double knockout (DKO) 
MEFs were serum-starved and treated with 1 µM ICI118551 (ICI) or 10 µM 
isoproterenol (ISO) for 10 min at 37oC, then lysed, as described in methods. Cell 
lysates were analyzed by Western using indicated primary antibodies. B. DKO 
MEFs were infected with retrovirus encoding GFP (control, -), WT arrestin-2 
(WT), or arrestin2-Arg307Ala mutant (R307A). 48 hours post-transfection the 
cells were serum-starved for 2 hours, stimulated with 1 µm ICI118551 for 10 min 
at 37oC, lysed, and analyzed by Western blot. Means + SD of 3-4 independent 
experiments are shown in bar graphs; representative blots are shown below.  
* p<0.05, ** p<0.01, *** p<0.001. 
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Thus, the observed reduction in c-Raf1 binding to the arrestin-2-
Arg307Ala mutant (Fig. 8A) translates into a complete loss of the ability to 
productively scaffold the c-Raf1-MEK1-ERK1/2 signaling cascade, suggesting 
that Arg307 in arrestin-2 plays a critical role in the binding of c-Raf1 and 
promoting ERK1/2 activation.  
 
Arrestin-2 and Arrestin-3 scaffold c-Raf1 by different molecular 
mechanisms 
Interestingly, the homologous arrestin-3 residue is a lysine, and Lys308 
points in a different direction as suggested by the crystal structure of arrestin-3 
(Fig. 10) (Zhan, Gimenez et al. 2011). To test whether this distinct conformation 
translates into a different role of this residue in the arrestin-3-dependent 
scaffolding of the c-Raf1-MEK1-ERK1/2 module, we constructed arrestin-3-
K308A mutant. We found that this mutation does not significantly affect the ability 
of arrestin-3 to bind the model receptor, light-activated phosphorhodopsin (Fig. 
12A). We then compared the ability of WT arrestin-3 and its K308A mutant to 
interact with co-expressed c-Raf1 in COS7 cells. We found that both proteins co-
immunoprecipitate similar amounts of c-Raf1 (Fig. 12B,C), suggesting that the 
role of this positively charged residue in arrestin-3 is different. To test whether an 
equivalent binding of c-Raf1 translates into similar ability of arrestin-3 and K308A 
mutant to promote the activation of endogenous ERK1/2 in an arrestin-
dependent manner, we expressed both proteins in arrestin-2/3 DKO MEFs, and 
challenged endogenous β2AR with an arrestin-biased agonist ICI118551 (Fig. 
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13). Our findings confirmed that DKO MEFs do not elicit ERK1/2 activation in 
response to ICI118551. The expression of WT arrestin-3 and its K308 mutant 
rescued ERK1/2 response to ICI118551 virtually to the same extent (Fig. 13). 
Thus, the Lys308 residue in arrestin-3 does not appear to play a critical role in c-
Raf1 binding and ERK1/2 phosphorylation (Fig. 12, Fig. 13), in contrast to the 
homologous Arg307 residue in arrestin-2 (Figs. 9, 11). These data suggest that 
even though both non-visual arrestins scaffold c-Raf1-MEK1-ERK1/2 cascade, 
fine molecular mechanisms of their action are distinct. 
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Figure 12. Distinct functional role of homologous positive charge in 
arrestin-3. A. The binding of WT arrestin-3 and K308A mutant to P-Rh*. Means 
+/- SD of three experiments performed in duplicate are shown. B. Flag-tagged 
WT arrestin-3 and K308A mutant were co-expressed with HA-tagged c-Raf1 in 
COS7 cells. Arrestins were immunoprecipitated with anti-Flag antibody, and co-
immounoprecipitated c-Raf1 was visualized by Western blot with anti-HA 
antibody. The results of a representative experiment are shown. C. The intensity 
of c-Raf1 band in the immunoprecipitate was quantified. Means + SD of 3 
independent experiments are shown.  
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Figure 13. β2AR-mediated ERK activation by arrestin-3 and arrestin-3-
Lys308Ala. DKO MEFs were infected with retrovirus encoding GFP (control, -), 
WT arrestin-3 (A3-WT), or arrestin-3-Lys308Ala mutant (K308A). 48 hours post-
transfection the cells were serum-starved for 2 hours, stimulated with 1 µm 
ICI118551 for 10 min at 37oC, lysed, and analyzed by Western blot. Means + SD 
of 3 independent experiments are shown in bar graphs; representative blots are 
shown below. *** p<0.001. 
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To test whether the mutations in non-visual arrestins change the time course of 
receptor-dependent ERK1/2 activation, rather than just maximum response, we 
used DKO MEFS expressing GFP (control), WT arrestin-2, arrestin-2-R307A, WT 
arrestin-3, or arrestin-3-K308A mutants (Fig. 14). We found that in all cases peak 
ERK1/2 phosphorylation was observed at 5 min of ICI118551 treatment, and by 
20 min ERK1/2 activity returned back to basal (Fig. 14 A,C). In control GFP-
expressing DKO MEFs no ERK1/2 activation in response to ICI118551 was 
detected, once more demonstrating that this effect is strictly arrestin-dependent. 
Thus, ERK1/2 activation triggered by arrestin-biased β2AR agonist ICI118551 in 
MEFs is rapid and transient. The time courses confirm that arrestin-2-R307A 
mutant does not promote ERK1/2 phosphorylation, in contrast to both WT non-
visual arrestins and arrestin-3-K308A mutant. Relatively higher ERK1/2 
phosphorylation mediated by WT arrestin-2 likely reflects its ~3-fold higher 
expression level than that of arrestin-3 (Fig. 14B). 
 
 
 
 
 
 
 
 
 
   
45 
 
 
 
 
 
 
 
 
Figure 14. Rapid arrestin-mediated ERK1/2 activation by ICI118551 via β2-
adrenergic receptor. A. DKO MEFs were infected with retrovirus encoding GFP 
(control), WT arrestin-2 (A2-WT), arrestin-2-Arg307Ala (R307A), WT arrestin-3 
(A3-WT), or arrestin-3-Lys308Ala (K308A). 48 hours postinfection DKO-MEFs 
were serum-starved for 2 hours and stimulated with 1 µM ICI118551 for 0, 5, 10 
and 20 min at 37oC. Cells were then lysed and analyzed by Western blot. 
Representative blot for phospho-ERK is shown. B. The expression of WT and 
mutant arrestins was compared by Western blot. Mutants and corresponding 
parental WT arrestins express at the same level. However, the expression of 
both forms of arrestin-2 is ~3-fold higher than that of both forms of arrestin-3. C. 
Time course of ERK1/2 activation in DKO MEFs expressing GFP (control) or 
indicated arrestins. Means + SD of two independent experiments are shown. 
Statistical significance of the differences (as compared to corresponding zero 
time point) is shown, as follows: **, p<0.01; ***, p<0.001. 
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DISCUSSION 
Non-visual arrestins facilitate the activation of several MAP kinases in 
response to GPCR activation, including JNK3 (McDonald, Chow et al. 2000), 
ERK1/2 (Luttrell, Roudabush et al. 2001), and p38 (Bruchas, Macey et al. 2006). 
Multiple GPCRs have been shown to activate ERK1/2 in an arrestin-dependent 
manner, including β2AR (Shenoy, Drake et al. 2006), angiotensin type 1A 
receptor (Ahn, Shenoy et al. 2004), µ-opioid receptor (Macey, Lowe et al. 2006), 
and the protease-activated receptor-2 (DeFea, Zalevsky et al. 2000).  
Based upon our identification of kinase-binding elements in arrestins, we 
have proposed a novel model of arrestin-dependent assembly of the MAPK 
signaling module. Arrestin binds all three kinases, assembling MAPKKK, 
MAPKK, and MAPK along its short axis, with each kinase directly interacting with 
both domains of arrestin. The relative size of arrestin and the kinases suggests 
that an individual arrestin molecule can assemble only one MAPK signaling 
module.  
Our studies, as well as others, have shown that free arrestins also bind 
ASK1, JNK3, MKK4, c-Raf1, MEK1, and ERK2 (Miller, McDonald et al. 2001; 
Scott, Le Rouzic et al. 2002; Wang, Wu et al. 2003; Song, Raman et al. 2006; 
Song, Gurevich et al. 2007; Li, Macleod et al. 2009; Meng, Lynch et al. 2009; 
Song, Coffa et al. 2009). Interestingly, while the interaction of ASK1, MKK4, and 
JNK3α2 with free arrestin-3 translates into JNK3 phosphorylation (Miller, 
McDonald et al. 2001; Song, Coffa et al. 2009), receptor-independent ERK 
activation by free arrestins has not been observed. This may be due to a very low 
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affinity of ERK for free arrestin2 and -3 (Song, Coffa et al. 2009) (Fig. 5). 
Structurally, arrestins are elongated molecules with two cup-like domains (Hirsch, 
Schubert et al. 1999; Han, Gurevich et al. 2001; Milano, Pace et al. 2002; Sutton, 
Vishnivetskiy et al. 2005; Zhan, Gimenez et al. 2011). All identified receptor-
binding elements are localized on the concave side of both domains (Ohguro, 
Palczewski et al. 1994; Gurevich and Benovic 1995; Gurevich, Dion et al. 1995; 
Pulvermuller, Schroder et al. 2000; Vishnivetskiy, Hosey et al. 2004; Hanson, 
Francis et al. 2006; Hanson and Gurevich 2006; Vishnivetskiy, Francis et al. 
2010; Vishnivetskiy, Gimenez et al. 2011), suggesting that binding partners 
recruited to the arrestin-receptor complex engage the opposite convex surface of 
the molecule (Fig. 8A, Fig. 10).  
Although the structure of arrestin suggests that the functions mediated by 
different surfaces can be modulated independently of each other by specific 
mutations (Pan, Gurevich et al. 2003; Gurevich and Gurevich 2010), alanine-
scanning mutagenesis of the conserved residues on the non-receptor-binding 
side of arrestin-2 revealed numerous mutations that significantly affected 
receptor binding (Fig. 7). Thus, targeted design of arrestins with desired 
functional characteristics may be a more complex endeavor than previously 
thought: it appears that the basal conformation of arrestin-2 is stabilized by an 
intricate network of interactions that spans both the receptor- and kinase-binding 
surfaces. The functional coupling of these two interfaces needs to be further 
explored experimentally. Therefore, for the analysis of arrestin-2 interactions with 
c-Raf1, MEK1, and ERK1/2 we only used ten mutants that demonstrated normal 
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receptor binding (Fig. 8B), indicative of proper folding. Nine of these showed 
essentially WT interactions with all three kinases in the c-Raf1-MEK1-ERK1/2 
pathway, whereas c-Raf1 binding was selectively impaired by the Arg307Ala 
mutation (Fig. 9). Although these data do not suggest that Arg307 is the only 
residue involved in c-Raf1 interaction, it appears to be an important docking point 
for this kinase.  
Arg307 is located at the inter-domain interface, and in most structures of 
arrestin-2, this residue interacts with Asp29 forming an inter-domain bridge (Fig. 
10). This interaction is quite long, ranging from 3.5 to 5.8 Å, and likely contributes 
little energy to the crystallographically observed conformations. In arrestin-2 
structures G4M (Han, Gurevich et al. 2001), G4R (Han, Gurevich et al. 2001), 
1ZSH (Milano, Kim et al. 2006), and 3GDI (Kang, Kern et al. 2009) the interaction 
is present, but it is absent in 3GC3 (Kang, Kern et al. 2009) and 1JSY (Milano, 
Pace et al. 2002). The interaction is observed in 1AYR, the only arrestin-4 
structure (Sutton, Vishnivetskiy et al. 2005). Arrestin-1 and -3 do not form this 
interaction in the crystals, although Arg307 is substituted by lysine in arrestin-3 
and arrestin-1, preserving positive charge (Wu, Hanson et al. 2006). Our 
observation that Arg307Ala is impaired in c-Raf1 binding and unable to promote 
detectable ERK1/2 activation indicates that in the c-Raf1 bound state, Arg307 
interacts with c-Raf1, rather than with Asp29. Arg307 is localized on the 
periphery of the interface between the N- and C- domains (Fig. 10). Its interaction 
with Asp29 can bridge the two domains, but is likely one of many weak 
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interactions that stabilize the basal arrestin conformation and are broken upon 
receptor binding (Gurevich and Gurevich 2004).  
We have shown that ERK1/2 activation via endogenous β2AR stimulated 
by ICI118551 in MEFs is strictly arrestin-dependent (Fig. 11A). Using this model, 
we demonstrated that impaired c-Raf1 binding results in the inability of the 
Arg307Ala mutant to scaffold productively the c-Raf1-MEK1-ERK1/2 cascade 
(Fig. 11B), despite its normal ability to bind receptor, MEK1, and ERK2 (Figs. 8, 
Fig. 9). Interestingly, Arg307Ala shows a tendency to act as a dominant-negative 
mutant, reducing overall ERK1/2 activity in MEFs (Fig. 10B), likely via 
sequestering MEK1 and/or ERK1/2, both of which bind normally to this mutant 
(Fig. 9B,C). Thus, as far as ERK1/2 activation is concerned, arrestin-2- 
Arg307Ala is the first signaling-biased arrestin constructed. Importantly, this 
function of arrestin-2 was selectively suppressed by a point mutation, which did 
not appreciably affect arrestin-2 binding to MEK1, ERK2, or receptor. However, 
we did not test many other reported arrestin-2 functions, so it is conceivable that 
its interactions with some other partners were also affected. The analysis of the 
time course of arrestin-mediated ERK1/2 activation via endogenous β2AR 
stimulated by ICI118551 in MEFs shows that WT arrestin-2 and arrestin-3, as 
well as arrestin-3-Lys308Ala mutant, comparably rescue ERK1/2 activation at all 
time points tested, whereas arrestin-2-Arg307Ala is consistently inactive (Fig. 
14). Thus, the differences between arrestin-2-Arg307Ala and arrestin-3-
Lys308Ala mutants to facilitate ERK1/2 phosphorylation at 10 min (Figs. 11, 12) 
reflect their inherent activity, rather than different kinetics of the response. 
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Interestingly, we found that ERK1/2 activation by ICI118551 in MEFs, which we 
showed to be strictly arrestin-mediated (Fig. 11A), is transient: the response 
reaches the peak at 5 min and rapidly declines, returning to the basal level by 20 
min (Fig. 14). ERK can be activated by GPCRs via distinct G protein- and 
arrestin-mediated mechanisms (Luttrell 2003). Several previous studies using 
over-expressed angiotensin II (Ahn, Shenoy et al. 2004), β2AR (Shenoy, Drake 
et al. 2006), and parathyroid hormone receptors (Gesty-Palmer, Chen et al. 
2006) suggested that ERK activation via G proteins is rapid and transient, 
whereas arrestin-mediated ERK1/2 activation is slow, but prolonged. However, 
ERK1/2 activation by endogenous M3 muscarinic receptor via Gq in HEK293 
cells was recently shown to be as long-lasting as previously reported arrestin-
mediated activation (Luo, Busillo et al. 2008). We found that arrestin-mediated 
ERK1/2 phosphorylation in MEFs is rapid and fades away in less than 20 min 
(Fig. 14), i.e., essentially as quickly as previously reported G protein-mediated 
ERK1/2 activation in other cell types. Importantly, in our experiments ERK1/2 
was activated in response to the stimulation of β2AR, the same receptor that was 
previously reported to induce prolonged arrestin-mediated ERK1/2 activation in 
HEK293 cells (Shenoy, Drake et al. 2006). Previous studies used four different 
GPCRs (Ahn, Shenoy et al. 2004; Gesty-Palmer, Chen et al. 2006; Shenoy, 
Drake et al. 2006; Luo, Busillo et al. 2008), so that distinct kinetics of G protein-
mediated ERK1/2 activation could be explained by the use of different receptors 
(Gurevich and Gurevich 2008). However, here we used the same β2AR as 
Shenoy et al (Shenoy, Drake et al. 2006), yet found very different timing of 
   
51 
arrestin-mediated ERK1/2 phosphorylation (Fig. 14). The fact that we activated 
ERK1/2 via endogenous β2AR expressed at fairly low level, whereas Shenoy et 
al (Shenoy, Drake et al. 2006) over-expressed WT and mutant β2AR could have 
contributed to this difference. Conceivably, cellular context also affects the time 
course of ERK1/2 activation via a particular pathway at least as much as the 
subtype of activated GPCR. Our finding that alanine substitution of the 
homologous positively charged residue in arrestin-3, Lys308, does not affect the 
ability of this subtype to bind c-Raf1 and promote ERK1/2 activation (Figs. 12, 
13) is the first demonstration that when both non-visual arrestins perform the 
same function, the two subtypes employ distinct molecular mechanisms. 
Structurally, several elements in arrestins appear to be fairly flexible, assuming 
distinct conformations not only in different arrestin subtypes, but even in different 
monomers within crystal oligomer (Zhan, Gimenez et al. ; Hirsch, Schubert et al. 
1999; Han, Gurevich et al. 2001). Therefore, these differences are often 
dismissed as mere indication of the plasticity of certain elements in the protein. 
However, our data suggest that subtle structural differences between arrestin-2 
and -3 (Fig. 10) (Zhan, Gimenez et al.) revealed by the crystal structures can 
have significant functional consequences. 
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CHAPTER IV 
 
ARRESTIN CONFORMATION AND RECEPTOR BINDING DETERMINE THE 
RECRUITMENT OF c-Raf1, MEK1, AND ERK2 ACTIVATION. 
 
INTRODUCTION 
Arrestins were first discovered as proteins that bind active phosphorylated 
G-protein coupled receptors (GPCRs) and stop (“arrest”) G protein-mediated 
signaling (Wilden, Hall et al. 1986) due to direct competition with G proteins for 
the cytoplasmic tip of the receptor (Wilden 1995; Krupnick, Gurevich et al. 1997).  
In the last 15 years arrestin interactions with many non-receptor partners have 
been described, suggesting that arrestins serve a versatile signaling regulators in 
the cell (reviewed in (Gurevich and Gurevich 2006; DeWire, Ahn et al. 2007)). 
Crystal structures of all four vertebrate arrestins (Hirsch, Schubert et al. 1999; 
Han, Gurevich et al. 2001; Milano, Pace et al. 2002; Sutton, Vishnivetskiy et al. 
2005; Zhan, Gimenez et al. 2011) revealed very similar basal conformation: an 
elongated molecule consisting of two cup-like domains connected by highly 
conserved intra-molecular interactions. Many groups using a variety of methods 
invariably mapped receptor-binding elements to the concave sides of both 
arrestin domains (Ohguro, Palczewski et al. 1994; Pulvermuller, Schroder et al. 
2000; Vishnivetskiy, Hosey et al. 2004; Hanson, Francis et al. 2006; Hanson and 
Gurevich 2006; Vishnivetskiy, Francis et al. 2010; Vishnivetskiy, Gimenez et al. 
2011). Receptor binding induces a significant conformational change, involving 
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the release of the arrestin C-tail and other rearrangements (reviewed in 
(Gurevich and Gurevich 2004; Hanson, Francis et al. 2006)). Interestingly, 
microtubule binding, mediated by the same concave sides of the two domains 
(Hanson, Cleghorn et al. 2007), induces a distinct conformational rearrangement 
(Hanson, Francis et al. 2006; Hanson, Cleghorn et al. 2007). Thus, in the cell 
arrestins exist in at least three distinct conformations, free, receptor-bound or 
microtubule-bound (Gurevich, Gurevich et al. 2008), and many signaling proteins 
differentially bind arrestins in these states (Song, Raman et al. 2006; Song, 
Gurevich et al. 2007; Ahmed, Zhan et al. 2011).  
Specific mutants of both arrestin-2 and arrestin-3 mimicking microtubule-
associated and receptor-bound conformations were constructed (Gurevich 1998; 
Vishnivetskiy, Schubert et al. 2000; Vishnivetskiy, Hirsch et al. 2002; Carter, 
Gurevich et al. 2005; Hanson, Francis et al. 2006; Song, Raman et al. 2006; 
Hanson, Cleghorn et al. 2007). Here we used wild type (WT) non-visual arrestins 
and their confromationally restricted mutants to determine the states that 
preferentially bind individual kinases of c-Raf1-MEK1-ERK2 cascade in the 
presence or absence of activated β2-adrenergic receptor (β2AR). We found that 
that the affinity of arrestin-2/3 for ERK2 dramatically increases when arrestins are 
associated with β2AR. Arrestin-2 interaction with c-Raf1 is enhanced by arrestin 
binding to the receptor, but arrestin-3-c-Raf1 interaction is not. MEK1 interaction 
also does not show clear preference for receptor-bound arrestin. Using pure 
proteins we present the first evidence that the interaction of arrestins with ERK2 
is direct, and that it is differentially affected by receptor binding. These findings 
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improve our understanding of arrestin-mediated scaffolding of MAP kinase 
cascades and pave the way for targeted manipulation of this branch of GPCR 
signaling. 
 
METHODS 
Protein purification and in vitro interactions of purified proteins 
Rhodopsin was purified from cow eyes, phosphorylated, and regenerated 
by 11-cis-retinal generously supplied by Dr. R. K. Crouch (Medical University of 
South Carolina, Charleston, SC), as described (Vishnivetskiy, Raman et al. 
2007). Bovine arrestins were expressed in E. coli and purified, as described 
(Hanson, Francis et al. 2006; Vishnivetskiy, Gimenez et al. 2011; Zhan, Gimenez 
et al. 2011). Active MEK1, active and inactive ERK2 were expressed in E. coli 
and purified, as described (Vishnivetskiy, Gimenez et al. ; Zhan, Gimenez et al. ; 
Hanson, Francis et al. 2006).  
 
ERK2 interaction with the receptor-bound arrestins 
Active (phosphorylated at T183 and Y185 by MEK1) or inactive ERK2 (30 
pmol) was preincubated with or without 30 pmol of purified arrestins for 20 min at 
30oC, then phosphorylated rhodopsin (50 pmol) was added and incubated in the 
light (to produce P-Rh*) for 5 min. Rhodopsin-containing membranes were 
pelleted through 0.2 M sucrose cushion, dissolved in SDS sample buffer, and 
pelleted ERK2 (1/300 of each sample) was quantified by Western blot using anti-
ERK antibodies (Cell Signaling) and purified ERK2 as a standard.  
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ERK2 interaction with the free arrestins  
CNBr-activated Sepharose beads (30 µl) containing 9 µg of covalently 
attached active phosphorylated (without or with 1 mM ATP) or inactive ERK2 
were incubated with 3 mg of indicated purified arrestins in 60 µl of binding buffer 
(50 mM Tris-HCl, pH 7.4, 100 mM KCl, 1 mM EGTA, 1 mM DTT) for 20 minutes. 
at 30oC. The beads were washed twice with 1 ml of ice-cold binding buffer 
supplemented with 0.01 mg/ml BSA and bound arrestins were eluted with SDS 
sample buffer and quantified by Western blot using respective purified arrestins 
as standards.  
 
ERK2 phosphorylation by purified MEK1  
ERK2 (12 pmol) was incubated with MEK1 (2 pmol) in 0.1 ml of 50 mM Hepes-
Na, pH 7.2, 100 mM NaCl, and 0.1 mM [γ-32P]ATP in the absence (control) or 
presence of 44 pmol of arrestin-2 or arrestin-3 for 30 min at 30oC. The reaction 
was stopped by MeOH-precipitation of the proteins. The pellet was dissolved in 
SDS sample buffer and subjected to SDS-PAGE. The gels were stained, dried, 
and exposed to X-ray film to visualize radiolabeled bands. ERK2 bands were cut 
out and 32P incorporation was quantified by scintillation counting. 
 
Co-immunoprecipitation and Western blotting  
Monkey kidney COS-7 cells were transfected with the indicated plasmids 
using Lipofectamine™ 2000 (Invitrogen; Carlsbad, CA), according to the 
manufacturers protocol (3 µL of Lipofectamine™ 2000 per 1 µg of DNA). 24 
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hours post-transfection, cells were serum-starved and lysed with lysis buffer 
(50mM Tris, 2mM EDTA, 250mM NaCl, 10% glycerol, 0.5% Nonidet P-40, 1mM 
NaVO3, 10mM N-ethylmaleimide, benzamidine and phenylmethylsulfonylfluoride) 
on ice for 20 min. Cell debris were pelleted by centrifugation for 10 min at 10,000 
x g. Lysates were precleared with 30 µl of protein G agarose, followed by 
incubation with either rabbit anti FLAG or rat anti HA antibody for 2 hours and by 
the addition of 30 µl of protein G-agarose beads for 2 hours. The beads were 
then washed 3 times with lysis buffer, and bound proteins were eluted with 
Laemmli SDS buffer. In experiments involving ERK2, prior to lysis the cells were 
treated with 1 mM cross-linking reagent dithiobis(succinimidyl propionate) (DSP; 
Pierce) for 30 min followed by 2 mM Tris-HCl, pH 7.5, for 15 min at room 
temperature. The proteins were separated by SDS PAGE (10%) and transferred 
to polyvinylidene difluoride membrane (Millipore, Bedford, MA). Blots were 
incubated with primary antibodies from Cell Signaling (mouse anti-HA (6E2) mAb 
#2367, or Sigma (mouse anti-FLAG M2, #F3165, 1:1500; rabbit anti-FLAG  
#F7425), followed by anti-mouse horseradish peroxidase-conjugated secondary 
antibodies from Jackson ImmunoResearch. Protein bands were visualized by 
enhanced chemiluminescence (ECL, Pierce) followed by exposure to X-ray film. 
The bands were quantified using VersaDoc with QuantityOne software (Bio-Rad 
Laboratories). 
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Arrestin-dependent ERK activation 
COS-7 cells 
COS-7 cells were transfected using Lipofectamine™ 2000 (Invitrogen; 
Carlsbad, CA), according to the manufacturer’s protocol (3 µL of Lipofectamine™ 
2000 per 1 µg of DNA) with Flag-tagged arrestin-2 together with ERK2-HA. 24-48 
hours post-transfection, cells were serum starved for 24 hours and then treated 
for 10 min at 37oC with saturating concentrations of isoproterenol (10µM), 
epinephrine (10µM), propranolol (10µM), alprenolol (1µM), ICI118551 (1µM) or 
carazolol (100nM). COS-7 were then harvested and lysed in 50mM Tris, 2mM 
EDTA, 100mM NaCl, 1% Nonidet P-40, supplemented with protease (Roche, 
04693124001) and phosphatase (Roche, 04906845001) inhibitors cocktails on 
ice for 20 min. 
 
Mouse embryonic fibroblasts (MEFs) 
For retrovirus production, human embryonic kidney (HEK) 293T cells were 
transfected using Lipofectamine™ 2000 (Invitrogen; Carlsbad, CA), according to 
the manufacturer’s protocol (3 µL of Lipofectamine™ 2000 per 1 µg of DNA) with 
the following constructs: pVPack-GP (Stratagene, 217566), pVack-VSV-G 
(Stratagene, 217567), together with pFB-arrestin-2, pFB-arrestin-2-Arg307Ala, 
pFB-arrestin-3, pFB arrestin-3-K308A, or pFB-GFP. 24-48 hours post-
transfection, media containing the virus produced by HEK293T cells was 
collected and used to infect arrestin-2/3 double knockout MEFs (a generous gift 
of Dr. R. J. Lefkowitz, Duke University) (Kohout, Lin et al. 2001). Fresh virus-
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containing media was used daily for 3 days. Then MEFs were serum starved for 
2 hours and treated with 1 µM ICI118551, a biased ligand of β2-adrenergic 
receptor (β2AR), which is an inverse agonist of G protein signaling and an 
agonist of arrestin recruitment (Azzi, Charest et al. 2003), or 10 µM β2AR agonist 
isoproterenol for 10 min at 37oC. MEFs were harvested and lysed in 50mM Tris, 
2mM EDTA, 100mM NaCl, 1% Nonidet P-40, supplemented with protease 
(Roche, 04693124001) and phosphatase (Roche, 04906845001) inhibitors 
cocktails on ice for 20 minutes.  
 
MATERIALS 
[γ-32P]ATP was from Perkin-Elmer. All restriction enzymes were from New 
England Biolabs. All other chemicals were from sources previously described 
(Gurevich and Benovic 2000; Coffa, Breitman et al. 2011). 
 
RESULTS 
ERK2 directly binds non-visual arrestins, and this interaction increases 
MEK1 phosphorylation of ERK2 
Although ERK2 interaction with arrestins was reported a decade ago 
(Luttrell, Roudabush et al. 2001), this interaction was never shown to be direct. 
Experiments shown in Fig.15 were used to test the direct interaction of ERK2 
with free arrestins. Active ERK (phosphorylated by MEK1) with or without ATP 
and inactive ERK2 was used to assess interaction with non-visual arrestins. As 
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expected, we did not detect ERK2 binding to WT visual arrestin-1 (Fig. 15), 
suggesting that either free arrestin-1 does not bind ERK2 or the affinity of this 
interaction is too low to keep it bound throughout the washing procedure. We 
observed that both non-visual arrestins bind with a comparably affinity to active 
ERK2. In addition, we noted that the presence of 1 mM ATP (ERK2 co-substrate) 
significantly reduced the binding of arrestin-2, but not that of arrestin-3 (Fig. 15), 
suggesting that inside the cell (where >2 mM ATP is always present) free 
arrestin-3 may bind ERK2 with higher affinity than arrestin-2. Despite the fact that 
both non-visual arrestins preferentially bind to active ERK2, arrestin-2 is 
significantly more selective (binding to inactive ERK2 is 33% of that to active 
form, whereas for arrestin-3 it is 67%).  
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Figure 15. ERK2 binds free wild type non-visual arrestins.  
A, Active (phosphorylated at T183 and Y185 by MEK1) or inactive ERK2 (30 
pmol) was preincubated with or without 30 pmol of indicated arrestin for 20 
minutes at 30oC, then phosphorylated rhodopsin (50 pmol) was added and 
incubated in the light (to produce P-Rh*) for 5 min. Rhodopsin-containing 
membranes were pelleted through 0.2 M sucrose cushion, dissolved in SDS 
sample buffer, and pelleted ERK2 (1/300 of each sample) was quantified by 
Western blot using anti-ERK antibodies (Cell Signaling) and purified ERK2 as a 
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standard. Abbreviations: VA, visual arrestin-1, A2, arrestin-2, A3, arrestin-3. B. 
Quantification of data shown in panel A. C, CNBr-activated Sepharose (30 µl) 
containing 9 µg of covalently attached active phosphorylated (without or with 1 
mM ATP) or inactive ERK2 were incubated with 3 µg of indicated purified 
arrestins in 60 µl of binding buffer (50 mM Tris-HCl, pH 7.4, 100 mM KCl, 1 mM 
EGTA, 1 mM DTT) for 20 min at 30oC. The beads were washed twice with 1 ml of 
ice-cold binding buffer supplemented with 0.01 mg/ml BSA and bound arrestins 
were eluted with SDS sample buffer and quantified by Western blot using 
respective arrestins as standards.  
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Next, we tested whether arrestin binding affects MEK1 phosphorylation of 
ERK2. Purified inactive (unphosphorylated) ERK2 and purified active MEK1 
(which phosphorylates ERK2) were used to reconstruct this module of c-Raf1-
MEK1-ERK1/2 cascade in vitro (Fig. 16). ERK2 phosphorylation by MEK1 was 
evaluated in the absence or presence of purified arrestins. We found that in the 
absence of arrestins MEK1 phosphorylates approximately 10 % of ERK2 present 
(Fig. 16). In the presence of arrestin-2 or arrestin-3 the extent of ERK2 
phosphorylation was increased by 33 or 41%, respectively. Thus, free non-visual 
arrestins moderately facilitate the phosphorylation of ERK2 by MEK1.  
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Figure 16. Free non-visual arrestins enhance ERK2 phosphorylation by 
MEK1. ERK2 (12 pmol) was incubated with MEK1 (2 pmol) in 0.1 ml of 50 mM 
Hepes-Na, pH 7.2, 100 mM NaCl, and 0.1 mM [γ-32P]ATP in the absence 
(control) or presence of 44 pmol of arrestin-2 (Arr2) or arrestin-3 (Arr3) for 30 min 
at 30oC. The reaction was stopped by MeOH-precipitation of the proteins. The 
pellet was dissolved in SDS sample buffer and subjected to SDS-PAGE. The 
gels were stained, dried, and exposed to X-ray film to visualize radiolabeled 
bands (upper panel). ERK2 bands were cut out and 32P incorporation was 
quantified by scintillation counting (lower panel). (**) p<0.01, as compared to 
control. 
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The effect of arrestin-2 and arrestin-3 interactions with β2AR on the binding 
of the three kinases in c-Raf1-MEK1-ERK2 cascade 
    The original description of scaffolding of c-Raf1-MEK1-ERK1/2 cascade 
by arrestins in response to receptor activation suggested that only receptor-
bound arrestins interact with c-Raf1 and ERK1/2, whereas MEK1 does not bind 
arrestins directly, but is recruited via c-Raf1 and ERK to the complex (Luttrell, 
Roudabush et al. 2001). However, subsequent studies suggested that all three 
kinases bind free non-visual arrestins, and that ERK demonstrates the lowest 
affinity of the three (Song, Coffa et al. 2009). MEK1 interaction with free arrestin-
2 was independently confirmed by another group (Meng, Lynch et al. 2009). 
However, the effects of arrestin-2 and -3 conformation and receptor binding on 
their interaction with these kinases were never systematically investigated. 
Therefore, we used two known conformationally biased forms of arrestin-2 and -
3, “pre-activated” 3A mutants (Kovoor, Celver et al. 1999; Celver, Vishnivetskiy et 
al. 2002; Pan, Gurevich et al. 2003) and and mutants “frozen” in the basal state 
by 7-residue deletion in the inter-domain hinge (∆7) (Vishnivetskiy, Hirsch et al. 
2002; Song, Raman et al. 2006; Hanson, Cleghorn et al. 2007; Song, Gurevich et 
al. 2007) to address this question in COS-7 cells expressing only endogenous 
β2AR, or additional plasmid-encoded β2AR at significantly greater level.  
      We found that the stimulation of endogenous β2AR by an agonist 
isoproterenol increased ERK2 binding to arrestin-2 and arrestin-3 (Fig. 17).  
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Figure 17. Conformational dependence of the interaction of non-visual 
arrestins with ERK2. COS-7 cells were transfected with WT, 3A, or ∆7 mutant 
forms of Flag-tagged arrestin-2 (A) or arestin-3 (B), along with ERK2-HA, with or 
without β2AR-HA. Cells were serum starved 24 hours after transfection, 
stimulated for 10 min at 37oC with 10 µM β2AR agonist isoproterenol. Arrestins 
were immunoprecipitated with anti-Flag antibody, and co-immunoprecipitated 
ERK2 and β2AR were detected with anti-HA antibody. Bar graphs show the ratio 
of co-immunoprecipitated ERK2 to immunoprecipitated arrestin. The data from 3 
independent experiments were statistically analyzed by ANOVA, and the 
significance of the differences is indicated, as follows: * or &, p<0.05; ** or &&, 
p<0.01, as compared to corresponding within group basal level of ERK2 co-
immunoprecipitation (black bars); a or $ or #, p<0.05 compared to WT control 
(black bar in WT group). 
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Interestingly, overexpression of β2AR resulted in the formation of an 
arrestin-receptor complex independent of isoproterenol stimulation and further 
increased the binding of ERK2 to arrestins (Fig. 17). Apparently, due to the 
known constitutive activity of β2AR (Samama, Cotecchia et al. 1993), its over-
expression induces arrestin/β2AR interaction that is not significantly enhanced by 
isoproterenol stimulation. Pre-activated 3A mutants bind ERK2 much better than 
corresponding wild type (WT) arrestins. Co-expression of β2AR with 3A mutants 
further enhanced arrestin-ERK2 interaction (Fig. 17). Unexpectedly, we found 
that ∆7 mutants of both arrestins also bind ERK2 significantly better than WT 
proteins or even 3A mutants (Fig. 17). This is consistent with the reported ability 
of ∆7 mutants of arrestin-2 and -3 to recruit ERK1/2 to microtubules, which they 
bind with high affinity (Hanson, Cleghorn et al. 2007). In agreement with impaired 
receptor binding of ∆7 mutants, we found that neither isoproterenol stimulation 
nor β2AR over-expression affected ERK2 binding to these mutants (Fig. 17). 
Thus, ERK2 preferentially interacts with arrestins in receptor-bound and 
microtubule-associated conformation, with free arrestins in the basal state having 
the lowest affinity for this kinase.  
      In contrast, we found that the isoproterenol, with or without β2AR over-
expression, did not affect MEK1 binding to WT arrestin-2, arrestin-3, and their ∆7 
mutants (Fig. 18). Interestingly, while the binding of the 3A mutants to MEK1 was 
not affected by isoproterenol stimulation of endogenous β2AR, receptor over-
expression dramatically increased the amount of MEK1 co-immunoprecipitated 
with 3A mutants of both arrestins (Fig. 18). Thus, receptor binding apparently 
   
67 
increases arrestin interactions with MEK1, and this effect becomes more 
prominent when arrestins are rendered conformationally loose by 3A mutation. 
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Figure 18. The binding of MEK1 is largely insensitive to arrestin 
conformation. COS-7 cells were transfected with WT, 3A, or ∆7 mutant forms of 
Flag-tagged arrestin-2 (A) or arestin-3 (B), along with MEK1-HA, with or without 
β2AR-HA. Cells were serum starved 24 hours after transfection, stimulated for 10 
minutes at 37oC with 10 µM β2AR agonist isoproterenol. Arrestins were 
immunoprecipitated with anti-Flag antibody, and co-immunoprecipitated MEK1 
and β2AR were detected with anti-HA antibody. Bar graphs show the ratio of co-
immunoprecipitated MEK1 to immunoprecipitated arrestin. The analysis of the 
data from 3 independent experiments by ANOVA, revealed the following 
differences: &, p<0.05, as compared to corresponding within group basal level of 
MEK1 co-immunoprecipitation (black bars). 
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In contrast to ERK2 and MEK1, the binding of c-Raf1 to WT arrestin-2 and 
-3 is differentially affected by β2AR over-expression (Fig. 19). In the case of 
arrestin-2 the presence of extra β2AR resulted in a dramatic increase in c-Raf1 
binding, whereas in the case of arrestin-3 receptor effect was only marginal (Fig. 
19). When arrestins were rendered conformationally flexible by 3A mutation, 
β2AR over-expression increased c-Raf1 binding to both arrestins comparably 
(Fig. 19). Similar to ERK2 and MEK1, more c-Raf1 co-immunoprecipitated with 
∆7 mutants than with WT forms of both arrestins. In the case of arrestin-2-∆7, 
even the effect of β2AR over-expression was significant, likely reflecting residual 
ability arrestin-2-∆7 to bind receptors (Hanson, Cleghorn et al. 2007).  
     To summarize, isoproterenol activation of the endogenous receptor 
present at relatively low levels resulted in a detectable increase of the interaction 
with WT arrestins only for ERK2 (Fig. 17), which was previously shown to have 
the lowest affinity for free arrestins (Song, Coffa et al. 2009). In contrast, massive 
expression of exogenous β2AR increased WT arrestin binding of ERK2 and c-
Raf1, but not MEK1 (Figs. 17-19). As could be expected, in the case of 3A 
mutants that mimic receptor-bound conformation and bind GPCRs more readily, 
the interaction with all three kinases is increased by receptor over-expression, 
whereas ∆7 with impaired receptor binding are essentially unresponsive to β2AR 
(Figs. 17-19). Unexpectedly, ∆7 mutants of arrestin-2 and -3 bind ERK2 and c-
Raf1 better than parental WT arrestins (Figs. 17, 19). The same tendency was 
observed with MEK1, although it did not reach statistical significance (Fig. 18).  
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Figure 19. Conformational dependence of arrestin interactions with c-Raf1. 
COS-7 cells were transfected with WT, 3A, or ∆7 mutant forms of Flag-tagged 
arrestin-2 (A) or arrestin-3 (B), along with c-Raf1-HA, with or without β2AR-HA. 
Cells were serum starved 24 hours after transfection, stimulated for 10 minutes 
at 37oC with 10 µM β2AR agonist isoproterenol. Arrestins were 
immunoprecipitated with anti-Flag antibody, and co-immunoprecipitated c-Raf1 
and β2AR were detected with anti-HA antibody. Bar graphs show the ratio of co-
immunoprecipitated c-Raf1 to immunoprecipitated arrestin. The differences 
revealed by the analysis of the data from 3 independent experiments by ANOVA 
are indicated, as follows: * or & or a, p<0.05, as compared to corresponding within 
group basal level of c-Raf1 co-immunoprecipitation (black bars); $ or #, p<0.05, 
compared to WT control (black bar in WT group). 
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Receptor-stimulated arrestin-dependent ERK activation 
     Next, we tested whether arrestin-ERK2 interaction correlates with 
receptor-dependent ERK2 activation. To this end, we expressed HA-ERK2 with 
arrestin-2-Flag (Fig. 20A) or arrestin-3-Flag (Fig. 20D) in COS-7 cells and 
stimulated endogenous β2AR with saturating concentrations of agonists 
(isoproterenol, epinephrine), antagonists (propranolol, alprenolol), or inverse 
agonists (ICI118551, carazolol). The amount of ERK2 co-immunoprecipitated 
with arrestin-2 (Fig. 20B) or arrestin-3 (Fig. 20E) was significantly increased by 
treatment with agonists, antagonists and inverse agonists. Importantly, the level 
of ERK2 phosphorylation was also increased by different ligands in cells 
expressing arrestin-2 (Fig. 20C) and arrestin-3 (Fig. 20F). Inverse agonists 
ICI118551 and carazolol induced the most dramatic increase in ERK2 
association with arrestins and significant increase in ERK2 activation (Fig. 20), 
supporting the idea that these compounds are in fact arrestin-biased ligands 
(Azzi, Charest et al. 2003). Presumed antagonists propranolol and alprenolol 
(that actually have partial agonist activity (Samama, Cotecchia et al. 1993)) also 
promoted ERK2 binding to arrestins and phosphorylation, albeit to a lesser 
degree (Fig. 20). Agonists isoproterenol and epinephrine produced 
disproportinally larger ERK2 activation relative to arrestin association (Fig. 20), 
likely because in contrast to other compounds tested these ligands increase G 
protein activation, and ERK can be also activated by GPCRs via G-protein 
mediated pathways (Luo, Busillo et al. 2008). 
 
   
72 
 
Figure 20. The effect of different β2AR ligands on the binding to arrestins 
and activation of ERK2. HA-tagged ERK2 was co-expressed with Flag-tagged 
WT arrestin-2 (A,B,C), or arrestin-3 (D,E,F). Cells were serum starved 24 hours 
after transfection and stimulated for 10 minutes at 37oC with 10 µM of indicated 
β2AR ligands. Arrestins were immunoprecipitated with anti-Flag antibody, and 
co-immunoprecipitated ERK2 was visualized with anti-HA antibody. The binding 
of ERK2 to arrestin-2 (B) or arrestin-3 (E) was significantly increased by 
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treatment with ligands. C,D. ERK1/2 activation in cell lysates was determined by 
Western blot with anti phospho-ERK1/2 antibody. Means + SD of 3-4 
independent experiments are shown in bar graphs; representative blots are 
shown in panels A and D. ANOVA with Bonferroni post-hoc test revealed the 
following differences: *, p<0.05; **, p<0.01; ***, p<0.001, as compared to 
untreated cells. 
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     Therefore, to exclude G protein-mediated mechanisms, we performed the 
next set of experiments in arrestin-2/3 double knockout (DKO) MEFs (Kohout, Lin 
et al. 2001), where ERK2 activation by β2AR inverse agonists is strictly arrestin-
dependent (Coffa, Breitman et al. 2011). An inverse β2AR agonist ICI118551, 
was previously shown to act as an arrestin-biased agonist (Azzi, Charest et al. 
2003). Indeed, we did not detect appreciable ERK1/2 activation by ICI118551 via 
endogenous β2AR in DKO MEFs (Fig. 21). We found that the expression of WT 
arrestin-2 rescues the ability of ICI118551 to stimulate ERK1/2 phosphorylation. 
Interestingly, arrestin-2-∆7 was also effective, in contrast to arrestin-2-3A mutant 
(Fig. 21).  
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Figure 21. WT and ∆7 mutant of arrestin-2 rescue b2AR-mediated ERK 
activation in response to ICI118551 in arrestin-2/3 double knockout MEFs. 
DKO MEFs were infected with retrovirus encoding GFP (control, -), WT arrestin-2 
(A2-WT), arrestin-2-3A (A2-3A), or arrestin-2-∆7 (A2- ∆7). The cells were serum-
starved 48 hours post-infection for 2 hours, stimulated with 1 µM ICI118551 for 
10 minutes at 37oC, lysed, and analyzed by Western blot. Means + SD of 3-4 
independent experiments are shown in bar graphs; representative blots are 
shown below. *, p<0.05; **, p<0.01. 
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     To determine which β2AR ligands enhance ERK1/2 phosphorylation in 
arrestin-dependent fashion, we compared ERK1/2 activation in DKO MEFs 
expressing GFP (control), WT arrestin-2, as well as ∆7 or 3A mutants (Fig. 
22A,B). In all cases we detected robust ERK1/2 activation in response to 
isoproterenol and epinephrine, further confirming that this effect is mediated by G 
protein, rather than arrestins. Only cells expressing WT arrestin-2 and ∆7 mutant 
showed ERK1/2 activation in response to ICI118551; however, we did not detect 
a statistically significant response to carazolol (Fig. 22A,B), which activated 
ERK1/2 in COS7 cells over-expressing arrestins (Fig. 20). To determine the 
possible reason for this difference, we compared the expression of arrestins in 
COS7 cells and DKO-MEFs, and found that the latter express all arrestins at 
much lower levels (Fig. 22C). Thus, ICI118551 appears to be more potent 
activator of arrestin-mediated signaling, effective even at fairly low arrestin 
expression levels.  
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Figure 22. ERK2 activation by different β2AR ligands in DKO MEFs. A. DKO 
MEFs were infected with retrovirus encoding GFP, WT arrestin-2 (A2-WT), 
arrestin-2-3A (A2-3A), or arrestin-2-∆7 (A2-∆7). Serum-starved cells were 
stimulated with indicated β2AR ligands, lysed, and analyzed by Western blot. 
Representative blots are shown. The expression of different forms of arrestin-2 is 
compared in the blot below. B. Phospho-ERK1/2 bands were quantified. Means + 
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SD of 3 independent experiments are shown. C. Comparison of arrestin 
expression levels in COS-7 cells (5 µg protein/lane) and DKO MEFs (10 µg 
protein/lane) was performed by Western blot with anti-arrestin antibody. 
Standards containing indicated amounts of purified arrestin-2 were run along with 
cell lysates to generate calibration curve. The following arrestin levels were 
detected in COS-7 cells: A2-WT, 100.1 pmol/mg; A2-3A, 81.1 pmol/mg; A2-∆7, 
92.8 pmol/mg. Arrestin expression in DKO MEFs was much lower: A2-WT, 13.2 
pmol/mg; A2-3A, 12.3 pmol/mg; A2-∆7, 21.7 pmol/mg. 
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DISCUSSION 
In addition to classical G protein-mediated signaling, GPCRs were shown 
to initiate several signaling pathways via bound arrestins, which lead to the 
activation of ERK1/2 (Luttrell, Roudabush et al. 2001), c-Jun N-terminal kinase 3 
(JNK3) (McDonald, Chow et al. 2000), and p38 (Bruchas, Macey et al. 2006). 
The ERK1/2 activating module consists of three kinases: c-Raf1, which 
phosphorylates MEK1, which in its turn phosphorylates ERK1/2 on both tyrosine 
and threonine residues (Boulton, Nye et al. 1991) within the activation loop. 
ERK1/2 activation by GPCRs can be mediated by the activation of Ras, PKC, 
tyrosine kinases (e.g., c-Src), trans-activation of receptor tyrosine kinases, or via 
arrestin scaffolds (DeWire, Ahn et al. 2007). 
ERK1/2 activity controls many cellular functions, including proliferation, 
differentiation, and apoptosis. Arrestin-mediated ERK1/2 activation may result in 
different physiological responses than those achieved by G protein activation.  G 
protein activation of ERK1/2 results in  the accumulation of these kinases (ERKs) 
within the nucleus, where they can phosphorylate and activate various 
transcription factors (Pierce, Luttrell et al. 2001) In contrast, when ERK1/2 
activation is promoted by arrestins, ERK1/2 is found mainly in cytoplasmic 
compartments of the cell where it can phosphorylate non-nuclear substrates 
(Tohgo, Pierce et al. 2002).  
Previously we have shown, using immunoprecipitation assays, that the 
binding of ERK2 to free arrestin is quite low and undetectable without the use of 
cross-linking (Song, Coffa et al. 2009). Here, using in vitro binding of purified 
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proteins, we have shown for the first time that ERK2 directly interacts with non-
visual arrestins (Fig. 15). Importantly, using purified protein we also observed an 
increase of phosphorylation of ERK2 by activated MEK1 in vitro in the presence 
of arrestin-2 and arrestin-3, as compared to control in the absence of arrestins 
(Fig. 16). This suggests two possible roles for arrestin: 1) binding of ERK2 to 
arrestin could change the conformation of ERK2, making it a better substrate for 
MEK1 (for example, it was recently shown using purified proteins that “scaffold” 
Ste5 in yeast acts by making MAPK Fus3 (but not related kinase Kss1) a better 
substrate for MAPKK Ste7, rather than by bringing Ste7 and Fus3 together 
(Good, Tang et al. 2009)); 2) both MEK1 and ERK2 can bind arrestin, and the 
binding facilitates the phosphorylation of ERK2 by bringing MEK1 to its substrate 
(true scaffolding; this mechanism was recently described for arrestin-3 
dependent increase in JNK3α2 phosphorylation by MKK4 (Zhan, Kaoud et al. 
2011)). 
To determine whether ERK2 binding is dependent upon arrestin 
conformation, we co-expressed ERK2 with the following three forms of arrestins: 
a) WT; b) “pre-activated” 3A mutants partially mimicking receptor-bound 
conformation (Gurevich 1998; Pan, Gurevich et al. 2003; Carter, Gurevich et al. 
2005); c) ∆7 mutants “frozen” in the basal conformation by the deletion of seven 
residues in the inter-domain hinge (Vishnivetskiy, Hirsch et al. 2002; Song, 
Raman et al. 2006; Hanson, Cleghorn et al. 2007). Our data suggest that β2AR 
binding-induced conformational change increases the affinity of ERK2 for both 
non-visual arrestins (Fig. 17). Unexpectedly, we found that ERK2 also binds ∆7 
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mutants with high affinity, demonstrating the lowest binding to free WT arrestins 
(Fig. 17). Both non-visual subtypes demonstrated the same conformational 
dependence of ERK2 binding (Fig. 17). Interestingly, we did not detect 
conformational dependence of MEK1 interactions with arrestin-2 or -3  (Fig. 18). 
In contrast, arrestin-2 binding to c-Raf1 is much more sensitive to its receptor 
interaction that that of arrestin-3 (Fig. 19). Since distinct structural features of 
arrestin-3 also result in lower selectivity for particular functional forms of the 
receptor than that of arrestin-2 (Zhan, Gimenez et al. 2011), these data suggest 
that higher conformational flexibility of arrestin-3 is responsible for more 
promiscuous interactions with GPCRs and other signaling proteins. Markedly 
different effects of receptor binding on arrestin-2 and -3 interaction with c-Raf1, is 
consistent with distinct ability of these subtypes to scaffold c-Raf1-MEK1-ERK1/2 
cascade (Ahn, Wei et al. 2004).  
To determine how receptor-dependent changes in arrestin interactions 
with these kinases translates into agonist-dependent ERK1/2 activation, we used 
β2AR that is endogenously expressed in most cultured cells at physiologically 
relevant levels, and took advantage of the availability of arrestin-biased agonists 
for this receptor (Azzi, Charest et al. 2003). Relatively low levels of endogenous 
arrestins in COS-7 cells ensure that exogenously expressed arrestin is the 
predominant species. We found that the expression of WT forms of arrestin-2 
and -3, which are the most sensitive to receptor interaction (Figs. 17-19), 
enhanced the phosphorylation of endogenous ERK1/2 in response to β2AR 
stimulation by unbiased agonists adrenaline and isoproterenol, antagonists (with 
   
82 
low agonist activity (Samama, Cotecchia et al. 1993)) alprenolol and propranolol, 
as well as arrestin-biased agonists carazolol and ICI118551 (Fig. 20). ERK1/2 
activation induced by carazolol and ICI118551, which are inverse agonists for G 
protein activation, is comparable to that induced by unbiased agonists that can 
act via G proteins and arrestins (Fig. 20), suggesting that a significant fraction of 
ERK1/2 is activated via arrestin-mediated scaffolding.   
To conclusively dissect arrestin-dependent and –independent 
mechanisms, we compared WT MEFs, where ERK1/2 can be activated via both 
pathways and DKO MEFs lacking both non-visual arrestins (Kohout, Lin et al. 
2001), where only G protein-mediated pathway is operative. Indeed, we found 
that while ERK1/2 phosphorylation in response to β2AR agonists that promote 
receptor coupling to G protein is essentially the same in WT and DKO MEFs, the 
response to ICI118551 is completely lost in DKO MEFs, indicating that it is 
mediated by non-visual arrestins absent in these cells (Fig. 21). The advantage 
of DKO MEFs is that one can be confident that the expressed form of arrestin is 
the only one present. For subsequent experiments we chose arrestin-2, which 
showed more pronounced changes in kinase interactions in response to receptor 
binding (Figs. 17-19). We found that both WT arrestin-2 and ∆7 mutant rescue 
ERK1/2 response to ICI118551 in DKO MEFs, whereas the 3A mutant does not 
(Fig. 21). Next we tested a wider range of β2AR ligands in DKO MEFs 
expressing GFP (control), WT arrestin-2, or 3A or ∆7 mutants (Fig. 22). We found 
that arrestin expression in DKO MEFs was 5-6 times lower than in COS7 cells 
(Fig. 22). In these conditions only ICI118551 induced robust ERK1/2 activation, 
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indicating that it is more potent stimulator of arrestin-mediated signaling than 
carazolol. 
To summarize, we determined conformational dependence of arrestin-2 
and -3 interactions with kinases c-Raf1, MEK1, and ERK2, which confirmed that 
ERK2 and c-Raf1 preferentially interact with the arrestin-receptor complex, and 
led to unexpected finding that the conformation of receptor binding-impaired ∆7 
mutants is favored by ERK2 and c-Raf1. Moreover, we found that both WT 
arrestin-2 and ∆7 mutants rescue arrestin-dependent activation of ERK1/2 in 
response to receptor stimulation by arrestin-biased ligands. Since dramatically 
reduced binding of ∆7 forms of arrestin-1, -2, and -3 was described using light-
activated rhodopsin, a form of receptor equally capable of coupling to G protein 
and arrestin, our data suggest that arrestin-2-∆7 is likely more capable of binding 
receptors in a distinct conformation induced by arrestin-biased agonists. Further 
structural dissection of receptor conformations preferentially engaging G proteins 
and arrestins requires the solution of crystal structures of receptors in complex 
with these two types of partners.  
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CHAPTER V 
 
CONCLUSIONS 
 
We have showed that the individual arrestin N- and C-domains, which can 
be expressed separately while still remaining functional (Gurevich and Benovic 
1992; Gurevich and Benovic 1993), interact with c-Raf1, MEK1 and ERK2 (Figs. 
5A-C) (Song, Coffa et al. 2009). The individual arrestin N- and C- domains also 
interact with ASK1, MKK4 and JNK3 (Song, Coffa et al. 2009). Recent studies 
have shown that MEK1 binds non-visual arrestins directly (Meng, Lynch et al. 
2009), contrary to what was previously believed (Pierce and Lefkowitz 2001). 
Taken together, these data suggest these kinases are arranged with their long 
axes parallel to the long axis of arrestin molecules (Figure 6).  
Arrestins are relatively small proteins with a significant proportion of their 
surfaces occupied by bound receptor. It is unlikely that kinases such as c-Raf1, 
MEK1, ERK2, ASK1, MMK4 and JNK3 bind arrestin simultaneously. We 
hypothesized that these cascades must compete with each other for the limited 
binding space available, suggesting that arrestin must somehow favor one 
partner over another. We expect competition between kinases of differing 
signaling cascades and positive cooperativity among kinases of the same 
cascade. Without such cooperativity arrestins would scaffold non-functional 
cascades.  
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We have tested this hypothesis using co-immunoprecipitation in COS-7 
cells (Fig. 23), but were not able to answer this question due to the presence of 
endogenous MAPK scaffolds such as endogenous arrestins and/or other 
scaffolds. A study using purified proteins, to compete for the in vitro binding of 
specific MAPK to arrestins will be necessary to show any cooperativity amongst 
members of the same MAPK cascades. 
Our mutagenesis studies of arrestin-2 have shown that the Arg307Ala 
mutant has reduced binding to c-Raf-1 (Fig. 9A), while still being capable of 
binding phosphorylated receptor (Figs. 7, 8B) and the downstream kinases 
MEK1 (Fig. 9B) and ERK2 (Fig. 9C) (Coffa, Breitman et al.). Although WT 
arrestin-2 was able to rescue ERK1/2 activation (Fig. 11B) in arrestin 2/3 double 
knock-out mouse embryonic fibroblasts (DKO MEFs), the Arg307Ala mutant 
failed to do so (Fig. 11B), suggesting that Arg307 is necessary for the interaction 
of c-Raf1 with arrestin-2. Interestingly, the corresponding residue on arrestin-3, 
lysine (K308), when mutated to an alanine, was able to rescue ERK1/2 activation 
in DKO MEFs similarly to WT arrestin-3 (Fig. 13), indicating that this residue is 
not essential for the interaction between c-Raf-1 and arrestin-3 (Coffa, Breitman 
et al.). Additionally, we reported that the arrestin-2/c-Raf1 interaction is enhanced 
upon receptor binding (Fig. 19A), whereas the arrestin-3/c-Raf1 interaction is not 
(Fig. 19B), thus highlighting a major difference between the non-visual arrestins 
in the scaffolding of MAPKs. 
Another major difference between the two non-visual arrestins is that 
Arrestin-2 C-terminus is known to be constitutively phosphorylated by ERK2, at 
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serine 412, whereas arrestin-3 is not (Lin, Krueger et al. 1997). This 
phosphorylation decreases the affinity for clathrin and thus dephosphorylation of 
Ser412 is necessary for receptor internalization to occur (Lin, Miller et al. 1999).  
With this in mind, we could use the R307A mutant, deficient in c-Raf1 
binding, and quantify levels of Ser412 phosphorylation and receptor 
internalization. Using this approach we could determine whether is necessary for 
arrestin-2 to scaffold the c-Raf1/MEK/ERK2 cascade in order for Ser412 to be 
phosphorylated, or whether other scaffolds can bring this cascade in close 
proximity to arrestin to mediate phosphorylation of this residue. 
Receptor-bound arrestin-3, as well as free arrestin-2 and arrestin-3, were 
shown to scaffold the ASK1–MKK4–JNK3 cascade (McDonald, Chow et al. 2000; 
Song, Coffa et al. 2009), whereas only free arrestin-3 appeared able to promote 
JNK3 activation (Song, Raman et al. 2006; Song, Coffa et al. 2009). This is also 
supported by the finding that an arrestin-3 mutant ‘frozen’ in the basal 
conformation was shown to promote JNK3 activation as well as WT arrestin-3 
(Song, Coffa et al. 2009). Moreover, our findings suggest that ERK2 does bind to 
free arrestin (Figs 5A, 9C, 15C), but this interaction is very weak and is 
significantly augmented by arrestin interaction with the β2AR (Figs. 17A, B).  
Arrestin was recently shown to mediate the regulation of additional 
receptor types beyond GPCRs, including the IGF1 receptor tyrosine kinase (Lin, 
Daaka et al. 1998) and the TGFβRIII receptor (Chen, Kirkbride et al. 2003). It 
may be possible that while the mechanism of arrestin binding to GPCRs is 
conserved in all arrestins, different structural elements are ultimately engaged in 
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arrestin complexes with different receptors. Arrestin might be able to adopt 
multiple conformations depending upon the family, class and/or type of receptor 
involved. The ability of arrestin to scaffold and activate MAPK could be tested 
with such receptors. Immunoprecipitation and direct in vitro binding studies 
involving different receptors types, arrestins, and MAPKs could help answer this 
question. 
Multiple GPCRs have been shown to activate ERK1/2 in an arrestin-
dependent manner, including the β2AR (Coffa, Breitman et al. ; Shenoy, Drake et 
al. 2006), the angiotensin type 1A receptor (Ahn, Shenoy et al. 2004), the µ-
opioid receptor (Macey, Lowe et al. 2006), and the protease-activated receptor-2 
(DeFea, Zalevsky et al. 2000). Our studies suggested that arrestin association 
with the β2AR significantly enhances both ERK2 binding (Fig.17) and activation 
(Figs. 11, 13, 14). We also reported that the interactions between free arrestin-2 
or arrestin-3 and ERK2 are very weak (Fig. 5), suggesting that the arrestin 
conformation change, upon receptor binding, is necessary for its interaction with 
ERK2. Arrestin-receptor interaction has been shown to induce the release of 
arrestin C-tail (Hanson, Francis et al. 2006), therefore studies involving 
mutagenesis within the arrestin C-tail will elucidate any residues comprising the 
C-tail that participate in ERK binding, increasing ERK affinity for the arrestin-
receptor complex. 
To determine how receptor-dependent changes in the arrestin interactions 
with MAPKs translate into agonist-dependent ERK1/2 activation, we used β2AR, 
endogenously expressed at physiologically relevant levels, and took advantage 
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of the available arrestin-biased agonists for this receptor (Azzi, Charest et al. 
2003). We found that the expression of WT arrestin-2 and WT arrestin-3 
enhanced the phosphorylation of endogenous ERK1/2 in response to β2AR 
stimulation by the unbiased agonists adrenaline and isoproterenol, antagonists 
(with low agonist activity (Samama, Cotecchia et al. 1993)) alprenolol and 
propranolol, as well as arrestin-biased agonists carazolol and ICI118551 (Fig. 
20). ERK1/2 activation induced by carazolol and ICI118551, which are inverse 
agonists for G protein activation, is comparable to that induced by unbiased 
agonists which can act via G proteins and arrestins (Fig. 20), suggesting that a 
significant fraction of ERK1/2 is activated via arrestin-mediated scaffolding.   
One final question that still remains unanswered is: How is ERK activation 
mediated by arrestins? One could speculate that the receptor serves as an 
anchor that brings arrestin close to the plasma membrane where c-Raf1 
becomes activated. This would result in ERK2 activation via MEK1. To test this 
hypothesis, generation of membrane-bound arrestin mutants that do not bind the 
receptor will be necessary, as well as determination of levels of ERK activation 
by such mutant. A membrane-bound arrestinR307A mutant, which we know does 
not interact with c-Raf1, could serve as a control for the quantification of basal 
ERK2 activation. Another possibility, in terms of arrestin activation of the ERK1/2 
signaling cascade, is that the conformation change in arrestin, due to receptor 
binding, may allow c-Raf1 homo/hetero-dimerization, which is known to be a 
necessary, yet to be fully understood, mode of activation. 
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The construction of arrestins capable of increasing ERK1/2 activity could 
have great therapeutic potential in neurodegenerative diseases, whereas 
arrestins specifically designed to activate JNK3 could be utilized to oppose the 
effects of excessive cell proliferation in cancer. 
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Figure 23. Arrestin-2 scaffolding MAPK cascades. COS-7 cells were 
transfected with plasmids encoding FLAG-tagged arrestin2, HA-tagged c-Raf1 
and MEK1, and GFP-tagged ERK2 and JNK3. ERK2 or JNK3 were 
immunoprecipitated with anti-GFP antibody, and precipitates were probed for HA, 
FLAG and GFP antibodies as shown.  
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